TW391952B - Guaiacoxypropanolamines with <alpha>/<beta>-adrenergic blocking activity - Google Patents

Guaiacoxypropanolamines with <alpha>/<beta>-adrenergic blocking activity Download PDF

Info

Publication number
TW391952B
TW391952B TW86114980A TW86114980A TW391952B TW 391952 B TW391952 B TW 391952B TW 86114980 A TW86114980 A TW 86114980A TW 86114980 A TW86114980 A TW 86114980A TW 391952 B TW391952 B TW 391952B
Authority
TW
Taiwan
Prior art keywords
phenoxy
propanol
amino
methoxy
compound
Prior art date
Application number
TW86114980A
Other languages
Chinese (zh)
Inventor
Ying-Jiun Chen
Original Assignee
Chen Ying Jiun
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chen Ying Jiun filed Critical Chen Ying Jiun
Priority to TW86114980A priority Critical patent/TW391952B/en
Application granted granted Critical
Publication of TW391952B publication Critical patent/TW391952B/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

A7 B7 五、發明説明( 經濟部中央標準局員工消費合作社印製 丨8ν.Λ修iA7 B7 V. Description of the invention (printed by the Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs 丨 8ν.Λ 修 i

R= CH2CH=CH2 . CH2=CHCOOC2H5 CH2NHCO(CH2)7 ch3 ch=chch3 本發明揭示合成化合物方法,其係包括 1.癒創木酚(guaiacol)之镇化反應,其原料為癒創 木酚(guaiacol)和二溴化乙烯,在反應後經氫氧化鈉溶液 調整酸鹼度(pH)到達7 ’以氣仿萃取、濃縮後液以矽膠充填 的管柱分離,並以己烷:乙酸乙酯為沖提液,得到白色結晶 產物(2 -(2 -曱氧基本氧基)乙基〉臭(2 - (2-Meth〇xyphenoxy_) ethylbromide)。 2 . 2- (2-甲氧基苯氧基)乙基溴、酞醯亞胺 (phthalimide)和二曱基乙酿胺(dimethylacetamide) 進行胺化反應’加熱迴流後倒入水中,將析出之固體過濾後 加入竣酸鉀溶液’加熱攪拌將得到的泥狀物過濾,並以水清 洗數次,以無水酒精再結晶得到白色結晶產物。取產物和聯 氨水合物(Hydrazine hydrate)於無水酒精中,加熱迴 流後置冷,過濾後經濃縮,再用氣仿萃取,經減壓濃縮,以 石夕膠充填的管柱分離’並以乙酸乙酯為沖提液,得到油狀產 物2_ (2—甲氧基苯氡基)乙基胺(2- Cethoxy-phen〇xy〉ethylamine)。 本纸浪尺度適用中國cns ) Θ (請先閱讀背面之注意事項再填寫本頁)R = CH2CH = CH2. CH2 = CHCOOC2H5 CH2NHCO (CH2) 7 ch3 ch = chch3 The present invention discloses a method for synthesizing compounds, which comprises a guaiacol hydration reaction. The raw material is guaiacol ( guaiacol) and ethylene dibromide. After the reaction, adjust the pH (pH) to 7 ′ with sodium hydroxide solution, extract with aerosol, and concentrate the liquid with a silica gel-filled column to separate it with hexane: ethyl acetate. The liquid was extracted to obtain a white crystalline product (2- (2-methyloxybenzyloxy) ethyl> smell (2- (2-Methoxxyphenoxy_) ethylbromide). 2. 2- (2-methoxyphenoxy) Ethyl bromide, phthalimide and dimethylacetamide are subjected to amination reaction 'heated under reflux and poured into water, the precipitated solid is filtered and added to the potassium acid solution', and the obtained The mud was filtered, washed several times with water, and recrystallized from anhydrous alcohol to obtain a white crystalline product. The product and Hydrazine hydrate were taken up in anhydrous alcohol, heated to reflux and left to cool, filtered, concentrated, and then Extraction with aerobic simulation, concentration under reduced pressure, The packed column was separated, and ethyl acetate was used as an eluent to obtain an oily product, 2- (ethoxyphenethyl) ethylamine. Applicable to China cns) Θ (Please read the notes on the back before filling this page)

經濟部中央標準局員工消費合作社印製 A7 ___________ B7 五、發明説明(i ) 產業上之利用領域 ,本發明係有關合成新穎之癒創木紛經基丙醇胺結構, 經動物實驗證實藥理上具有α/β-腎上腺素激性阻斷劑活 性。 背景 腎上腺素激性沒阻斷劑運用於臨床上已有26年的歷 史’目前’冷型阻斷劑除了使用在高血壓、心絞痛、心室 上心律不整等心血管疾病外,還被使用於甲狀腺毒症、心 肌肥大、心肌梗塞、偏頭痛、青光眼及胃腸道出血等症狀, 用途十分廣泛。但傳統性的々阻斷劑仍有一些不可避免 的’如:抑制β肌的功能、增加周邊及冠狀動脈血管阻力 等副作用,而限制了它的臨床用途,所以像冠狀動脈痙攣 造成的心絞痛,便不宜使用冷阻斷劑來治療。近年來發展 出來的兼併有0:阻斷、冷阻斷的藥物已經開始用於治療一 些心血管的疾病,它可以減少傳統卢阻斷劑的副作用,另 一方面,它也可以避免α阻斷劑產生血管擴張時造成的反 跳性心跳過速’一般提到最典型α '沒阻斷劑,就是^刺俾 塔(labetalol ’ Trandate®),臨床上常用於急性高血 壓(emergency hypertension)的病人。 本紙張尺度適用中國國家標华(CNS ) A4規格(210X29*7公釐) 3 (_先閱讀背面之注意Ϋ項再本頁) ——一—訂τPrinted by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs A7 ___________ B7 V. Description of the Invention (i) The field of industrial application. The present invention is related to the synthesis of novel guaiacene based on the structure of propylpropanolamine. It has been pharmacologically confirmed by animal experiments. Has α / β-adrenergic blocker activity. Background Adrenergic no blockers have been used clinically for 26 years. 'Current' cold blockers are used in addition to cardiovascular diseases such as hypertension, angina pectoris, and ventricular arrhythmia. They are also used in the thyroid gland. Symptoms such as poisoning, myocardial hypertrophy, myocardial infarction, migraine, glaucoma, and gastrointestinal bleeding are widely used. However, traditional tadpole blockers still have some unavoidable 'such as: inhibiting β-muscle function, increasing peripheral and coronary vascular resistance and other side effects, which limit its clinical use, so angina pectoris caused by coronary artery spasm, It should not be treated with cold blockers. Drugs developed in recent years have 0: block, cold block drugs have begun to treat some cardiovascular diseases, it can reduce the side effects of traditional Lu blockers, on the other hand, it can also avoid alpha block The pulsatile tachycardia caused by vasodilators is generally referred to as the most typical α 'without blocking agent, which is ^ thornetolol (Trandate®), which is commonly used clinically for acute hypertension patient. This paper size is applicable to China National Standards (CNS) A4 specification (210X29 * 7mm) 3 (_Please read the note on the back and then this page) ——One—Order τ

經濟部中央標準局員工消費合作社印策 3. 環氧化合物(Epoxide)的合成;由阿魏酸加入硫酸當 觸媒,及無水乙醇後加熱沸騰,於反應完全後加入氫化鈉 水溶液調整酸蜂度:(|H)值達到中性,減壓濃縮後以甲醇再結 晶,得到4_羥基-3-甲氧基桂皮酸乙酯(4妨办〇&gt;^-3-methoxycinnamic acid ethyl ester)。將產物溶於含氫氧化鈉之 絕對乙醇溶液中’加入表氯醇(epichlorohydrine)進行反應, 俟反應完成後進行減壓濃縮,濃縮液充填於矽膠管柱,運 用己烧:乙酸乙酯為沖提液,分離獲得粗結晶。反覆以己 烷再結晶,獲得純化之4-(2,3-環氧基丙氧基)·3-甲氧基桂皮 酸乙醋。 4. 產物的合成;取4-(2,3-環氧基丙氧基&gt;3_曱氧基桂皮 酸乙S曰及2-(2-甲氧基笨氧基)乙基胺溶於無水酒精,進行反 應。混合液經減壓濃縮,濃縮液以石夕膠充填的管柱分離, 濃縮可得到白色結晶產物。再溶入氫氧化鈉之丙酮溶液, 反應完全後,運用矽膠的管柱,分離,純化後獲得(^[(i 乙氧幾基乙烯基甲氧基)苯氧基曱氧基笨氧基乙基) 胺基]-2-丙醇。 新穎之癒創木酚羥基丙醇胺化合物化合物丨〜4 ; 化合物l...(H(4-烯丙基-2·曱氧基)笨氧基_3_[(2_甲氧基苯氧 基乙基)胺基-2 丙醇(1 -[(4_aiiyUmethDxy)pheiioxyI_:3_ 本紙張尺適用中國國—家標準(CNsyM規^ -------- 7 (請先閱讀背面之注意事項再填寫本頁) )______I______.--- 、-°. .I 1^1 II— -1- ^^1. A7 ____ B7 五、發明説明(2 ) 先前技術 在化學,结構與活性關係(SAR ,structure activity relation ship)的探討上顯示癒創木酚基乙 基丙醇胺(guaiacolethylamine)的結構具有α阻斷劑 的活性Augestein 等人在 1964 年;而 Kierstead,R.w. 等人在1983年J.Med.Chem.第26卷第1561-69頁報 〇方基經基丙醇胺(aryl〇xypropanolamine)是万阻 斷劑的基本結構。此外中國傳統生藥中許多成份都含有芳 香環,因此有興趣尋找一含有芳香環的成份,包括丁香油 盼(eugenol)、異丁香油酚(is〇eugen〇1)、阿魏酸 (ferulicacid)、番椒晶素(capSaicj_n),首先利用化 學反應導入丙醇胺(pr〇panol_amine)基團;接著導入部 分癒·創木盼基乙基丙醇胺(guaiac〇lethylainine)的結 構’使其具有α阻斷劑的活性,而合成丁香雙醇 (eugenodilol)、異丁香雙醇(j_s〇eugencjii〇i)、阿魏 雙醇(ferulidilol)、番椒雙醇(capSinodilol),並 進一步探討所合成的化合物是否具有α、万阻斷劑的活性 並探討其藥理的作用。 發明之目的 本發明首要目的在於揭示新穎之癒創木驗經基丙醇胺結 構,如式I所示, 尺度適用中國國家標隼) Α4現格(210X297公釐_) &quot; 4 A/ A/ ί)月 B7 五、發明説明 ; ^. 一 :;八..·丨 [(2-methoxyphenoxyethyl)amino]-2-propanol),簡稱 eugenodilol ° 化合物2.. .(H(4-乙氧羰基乙烯基-2-曱氧基)苯氧基-3-[(2-曱 氧基苯氧基乙基)胺基]-2-丙醇(1 -[(4-ethoxycarbonyl ··· ·冬·· ethenyl-2-methoxy)phenoxy]-3-[(2-metho^-phenoxyethyl) amino]-2-propanol) ° 化合物3....(l-[(4-壬醯胺甲基曱氧基)苯氧基_3-[(2-曱氧 基苯氧基乙基)胺基]-2-丙醇(1-[(4-11〇1^仙111丨(1咖6111)4-2-methoxy)phenoxy] -3 - [(2-methoxyphenoxyethyl)amino]-2-propanol),簡稱 capsinodilo卜 化合物4&quot;.(l-[(4-丙烯基-2-甲氧基)苯氧基-3-[(2-曱氧基苯氧 基乙基)胺基]-2-丙醇(l-[(4-propenyl-2-methoxy)· phenoxy]-3-[(2-methoxyphenoxyethyl)amino]-2-propanol) ,簡稱 isoeugenodilol 〇 化合物1Μ或其中間產物經再結晶後測定熔點(mp), 或再經由純化過程的產物分別測定其元素分析、質譜 (MS)、紅外線光譜(IR)、氫核磁共振光譜 CDCI3:)、紫外線吸收(ϋν)等物理化學數據可顯示該等化合 物具有明確之結構。 不同劑罝(1.0, 1.5, 3.0 mg/kg)之化合物皆可以 著下賊象,且作用時間 尽標準(CNS ) A4規格T&quot;2i〇x297公趁) 8 (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 訂---r ——,—線_| Ί!: A7 B7 經濟部中央標準局員工消費合作社印製 五、發明説明(3Instruction of the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 3. Synthesis of Epoxide; Ferulic acid is added as sulfuric acid as a catalyst, and anhydrous ethanol is heated to a boil. After the reaction is completed, sodium hydride aqueous solution is added to adjust the acidity. : (| H) value reached neutral, concentrated under reduced pressure and recrystallized with methanol to obtain ethyl 4-hydroxy-3-methoxycinnamic acid ethyl ester (4 to do 0 &gt; ^ -3-methoxycinnamic acid ethyl ester). The product was dissolved in an absolute ethanol solution containing sodium hydroxide. 'Epichlorohydrine was added to the reaction. After the reaction was completed, the reaction solution was concentrated under reduced pressure. The concentrated solution was filled in a silica gel column. The liquid was extracted and separated to obtain crude crystals. It was recrystallized with hexane repeatedly to obtain purified 4- (2,3-epoxypropoxy) · 3-methoxycinnamate ethyl acetate. 4. Synthesis of the product; 4- (2,3-epoxypropoxy &gt; 3-methoxy cinnamic acid ethyl ester and 2- (2-methoxybenzyloxy) ethylamine were dissolved in Anhydrous alcohol was reacted. The mixed solution was concentrated under reduced pressure, and the concentrated solution was separated by a column packed with Shixi gum, and concentrated to obtain a white crystalline product. It was then dissolved in an acetone solution of sodium hydroxide. After the reaction was completed, a silica gel tube was used. Column, separated, purified (^ [(i ethoxylvinylmethoxy) phenoxyfluorenyloxybenzyloxyethyl) amino] -2-propanol. Novel guaiacol hydroxy Propanolamine Compound Compounds 丨 ~ 4; Compound l ... (H (4-allyl-2 · fluorenyl) benzyloxy_3 _ [(2-methoxyphenoxyethyl) amino group- 2 Propanol (1-[(4_aiiyUmethDxy) pheiioxyI_: 3_ This paper rule applies to China's national standard (CNsyM regulations ^ -------- 7 (Please read the precautions on the back before filling this page)) ______I______ .--- 、-°. .I 1 ^ 1 II— -1 ^^ 1. A7 ____ B7 V. Description of the invention (2) The previous technology in SAR, structure activity relation ship Guaiacol ethylpropanol The structure of (guaiacolethylamine) has alpha blocker activity. Augestein et al., 1964; and Kierstead, Rw, et al., 1983, J. Med. Chem., Vol. 26, pp. 1561-69. Amylamine (aryloxyxyanolanol) is the basic structure of 10,000 blockers. In addition, many ingredients in traditional Chinese medicines contain aromatic rings, so it is interesting to find a component containing aromatic rings, including eugenol, isoeugenol (Is〇eugen〇1), ferulic acid (ferulicacid), capsaicin (capSaicj_n), first use a chemical reaction to introduce the propanol amine (propanol_amine) group; then introduce part of the guaiatropinyl ethyl The structure of guaiacol ethylainine 'makes it have the activity of an alpha blocker, and synthesize eugenodilol, j_soeeugencjiioi, ferulidilol, Capsinodilol, and further explore whether the synthesized compound has the activity of α, 10,000 blockers and explore its pharmacological effects. Purpose of the invention The primary purpose of the present invention is to reveal the novel guaiac tree experience The structure of propanolamine, as shown in formula I, the scale applies to Chinese national standard) Α4 is present (210X297 mm_) &quot; 4 A / A / ί) month B7 V. Description of the invention; ^. One :; eight. . · [(2-methoxyphenoxyethyl) amino] -2-propanol), referred to as eugenodilol ° Compound 2... (H (4-ethoxycarbonylvinyl-2-fluorenyloxy) phenoxy-3-[( 2-methoxyphenoxyethyl) amino] -2-propanol (1-[(4-ethoxycarbonyl · · · winter · ethenyl-2-methoxy) phenoxy] -3-[(2-metho ^ -phenoxyethyl) amino] -2-propanol) ° Compound 3 .... (l-[(4-nonylaminemethylmethyloxy) phenoxy_3-[(2-methyloxyphenoxy Ethyl) amino] -2-propanol (1-[(4-11〇1 ^ 仙 111 丨 (1 Coffee 6111) 4-2-methoxy) phenoxy] -3-[(2-methoxyphenoxyethyl) amino]- 2-propanol), abbreviated as capsinodilo compound 4 &quot;. (l-[(4-propenyl-2-methoxy) phenoxy-3-[(2-methoxyphenoxyethyl) amino] 2-propanol (l-[(4-propenyl-2-methoxy) · phenoxy] -3-[(2-methoxyphenoxyethyl) amino] -2-propanol), referred to as isoeugenodilol 〇 Compound 1M or its intermediate product is recrystallized After measuring the melting point (mp), or after purification The physical and chemical data such as elemental analysis, mass spectrometry (MS), infrared spectroscopy (IR), proton nuclear magnetic resonance spectroscopy (CDCI3 :), and ultraviolet absorption (ϋν) can be used to determine the structure of these compounds. Compounds with different dosages (1.0, 1.5, 3.0 mg / kg) can all act like a thief, and the action time is as standard (CNS) A4 size T &quot; 2i〇x297 as long as possible) 8 (Please read the precautions on the back before (Fill in this page) Printed by the Consumers 'Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs --- r ——, —line _ | Ί !: A7 B7 Printed by the Consumers' Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs

R= ch2ch=ch2 ch2=chcooc2h5 CH2NHCO(CH2)7 ch3 . ch=chch3 以及合成方法。 本發明另一目的,經動物實驗證實式I化合物具有 α//3-腎上腺素激性阻斷劑活性。 本發明尚有一目的,將式I化合物作為主成份添加 各種賦形劑,所製備之藥學組合物,具有α/々-腎上腺素 激性阻斷劑活性。 表之說明: 表1血壓的影響 表2血管鬆弛作用 表3對点1腎上腺素反應抑制作用 表4化合物之物理化學數據 圖1化合物之合成方法 發明之詳細說明 本發明揭示如式工所示新穎之癒創木酚羥基丙醇胺結 本紙張尺細中國國CNS } (請先閱讀背面之注意事項再填寫本頁〕R = ch2ch = ch2 ch2 = chcooc2h5 CH2NHCO (CH2) 7 ch3. Ch = chch3 and synthesis method. Another object of the present invention is to confirm that the compound of formula I has α // 3-adrenergic blocker activity through animal experiments. The present invention still has another object. The pharmaceutical composition prepared by using the compound of formula I as a main ingredient and various excipients has an α / α-adrenergic agonist blocking activity. Description of the table: Table 1 The effect of blood pressure Table 2 Vasodilator effect Table 3 The effect of adrenaline inhibition on point 1 Table 4 Physicochemical data of compounds Figure 1 Detailed description of the compound synthesis method of the invention Guaiacol hydroxypropanolamine paper ruler China CNS} (Please read the precautions on the back before filling in this page)

、π 5 Μ Μ 經濟部中央標準局員工消費合作社印製 Β7 五、發明説明(if ): --;— 予不同濃度_試化合麟㈤或1〇_s或ι〇_5μ),經作 用30分鐘後,再以去氧腎上腺素(L-phenylephrine) 完成累積性投藥。觀察不同濃度酬試化合物所造成的抑 制作用可得到EC50值。 (b) pA2值的計算: 同離體右心房實驗的計算方法。 對“腎上腺素反應(adrenergic response) 抑制作用之結果 在天竺鼠離體胸主動脈,累積投予去氧腎上腺素(l_ phenylephrine)可以使血管產生收縮的作用,測試藥物 在濃度lO'lG·5及i(r4 M ’可峨爭性的抑制去氧賢 上腺素(L-phenylephrine)的作用,接著由表3之 Schild plot得知:在離體血管測試藥物拮抗去氧腎上腺 素(L-phenylephrine)的收縮作用得到的pA2值。 實施例1 化合物1的合成 -4: —phend:入:4毫 耳氫氧化鈉,於7(TC下反應1 (請先閲讀背面之注意事項再填寫本頁)Π 5 Μ Μ printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs B7 V. Description of the invention (if):-;-Different concentrations of _ test chemical compound (1 / 10_s or ι〇_5μ), after action After 30 minutes, cumulative administration was completed with L-phenylephrine. EC50 values can be obtained by observing the inhibitory effects caused by test compounds at different concentrations. (b) Calculation of pA2 value: Calculation method of the right atrium experiment in vitro. As a result of the "adrenergic response" inhibitory effect, guinea pig isolated thoracic aorta, the cumulative administration of phenylephrine (l_phenylephrine) can cause blood vessel contraction, the test drug at a concentration of 10'lG · 5 and i (r4 M 'can suppress the effect of L-phenylephrine), and then learned from the Schild plot in Table 3: the test drug antagonizes L-phenylephrine in isolated blood vessels PA2 value obtained by the shrinkage effect of Example 1. Example 1 Synthesis of Compound-4: -phend: in: 4 mil sodium hydroxide, reacted at 7 (TC 1 (Please read the precautions on the back before filling this page )

17 A7 B7 五、發明説明( 經濟部中央標準局員工消費合作社印製 丨8ν.Λ修i17 A7 B7 V. Description of the invention (printed by the Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs 丨 8ν.Λ 修 i

R= CH2CH=CH2 . CH2=CHCOOC2H5 CH2NHCO(CH2)7 ch3 ch=chch3 本發明揭示合成化合物方法,其係包括 1.癒創木酚(guaiacol)之镇化反應,其原料為癒創 木酚(guaiacol)和二溴化乙烯,在反應後經氫氧化鈉溶液 調整酸鹼度(pH)到達7 ’以氣仿萃取、濃縮後液以矽膠充填 的管柱分離,並以己烷:乙酸乙酯為沖提液,得到白色結晶 產物(2 -(2 -曱氧基本氧基)乙基〉臭(2 - (2-Meth〇xyphenoxy_) ethylbromide)。 2 . 2- (2-甲氧基苯氧基)乙基溴、酞醯亞胺 (phthalimide)和二曱基乙酿胺(dimethylacetamide) 進行胺化反應’加熱迴流後倒入水中,將析出之固體過濾後 加入竣酸鉀溶液’加熱攪拌將得到的泥狀物過濾,並以水清 洗數次,以無水酒精再結晶得到白色結晶產物。取產物和聯 氨水合物(Hydrazine hydrate)於無水酒精中,加熱迴 流後置冷,過濾後經濃縮,再用氣仿萃取,經減壓濃縮,以 石夕膠充填的管柱分離’並以乙酸乙酯為沖提液,得到油狀產 物2_ (2—甲氧基苯氡基)乙基胺(2- Cethoxy-phen〇xy〉ethylamine)。 本纸浪尺度適用中國cns ) Θ (請先閱讀背面之注意事項再填寫本頁)R = CH2CH = CH2. CH2 = CHCOOC2H5 CH2NHCO (CH2) 7 ch3 ch = chch3 The present invention discloses a method for synthesizing compounds, which comprises a guaiacol hydration reaction. The raw material is guaiacol ( guaiacol) and ethylene dibromide. After the reaction, adjust the pH (pH) to 7 ′ with sodium hydroxide solution, extract with aerosol, and concentrate the liquid with a silica gel-filled column to separate it with hexane: ethyl acetate. The liquid was extracted to obtain a white crystalline product (2- (2-methyloxybenzyloxy) ethyl> smell (2- (2-Methoxxyphenoxy_) ethylbromide). 2. 2- (2-methoxyphenoxy) Ethyl bromide, phthalimide and dimethylacetamide are subjected to amination reaction 'heated under reflux and poured into water, the precipitated solid is filtered and added to the potassium acid solution', and the obtained The mud was filtered, washed several times with water, and recrystallized from anhydrous alcohol to obtain a white crystalline product. The product and Hydrazine hydrate were taken up in anhydrous alcohol, heated to reflux and left to cool, filtered, concentrated, and then Extraction with aerobic simulation, concentration under reduced pressure, The packed column was separated, and ethyl acetate was used as an eluent to obtain an oily product, 2- (ethoxyphenethyl) ethylamine. Applicable to China cns) Θ (Please read the notes on the back before filling this page)

經濟部中央標準局員工消費合作社印製 Γ、發明説。~~ ~~~~- 莫耳表氯醇(epicHiorohydrine),於相同條件下迴流2小時, 反應完成後減壓濃縮’其濃縮液濃縮液充填於矽膠管柱, 運用己烷:乙酸乙酯=1 : 9為沖提液,分離獲得到白色的 結晶。 &gt; . ' .¾ 取0.03莫耳3-[4_(2,3·環氧基丙氧基)_3_甲氧基]苯基丙 烯(3-[4-(2,3-epoxypropoxy)-3-methoxy]phenylpropene )及 5.0 克(0.03莫耳)2-(2-曱氧基苯氧基)乙基胺(2_(2_Meth〇xy-phenoxy)ethylamine)溶於無水酒精3〇毫升中,室溫下攪拌2 小時,以進行胺化反應。混合液經減壓濃縮,濃縮液以矽 膠充填的管柱分離’濃縮可得到白色結晶產物。取適量氫 氧化納溶於0.1%丙嗣,將上述白色結晶產物溶入,加熱至 沸騰,以薄層層析片(TLC)測定是否反應完全。將產物充填 於石夕膠的管柱,運用乙酸乙酯:甲醇=1 : 1比例之沖提液 分離,純化後獲得1-[(4-婦丙基-2-曱氧基)苯氧基-3-[(2-甲氧 基本氧基乙基)胺基-2-丙醇(1 -[(4-allyl-2-methoxy)phenoxy-3_ [(2-methoxy-phenoxyethyl)amino]-2-propanol) 實施例2 化合物3的合成 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公餐) 18 (請先閏讀背面之注意事項再填寫本頁} -裝. 訂 線Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs Γ, Invention. ~~ ~~~~-EpicHiorohydrine was refluxed under the same conditions for 2 hours. After the reaction was completed, the solution was concentrated under reduced pressure. The concentrated solution was filled in a silica gel column, and hexane: ethyl acetate = 1: 9 is the eluent, and white crystals are obtained by separation. &gt;. '.¾ Take 0.03 mole 3- [4_ (2,3 · epoxypropoxy) _3_methoxy] phenylpropene (3- [4- (2,3-epoxypropoxy) -3 -methoxy] phenylpropene) and 5.0 g (0.03 mole) of 2- (2-methoxyoxyphenoxy) ethylamine (2_ (2_Meth〇xy-phenoxy) ethylamine) dissolved in 30 ml of absolute alcohol at room temperature Stir for 2 hours to carry out the amination reaction. The mixed solution was concentrated under reduced pressure, and the concentrated solution was separated and concentrated using a silica-filled column to obtain a white crystalline product. Take an appropriate amount of sodium hydroxide and dissolve it in 0.1% propidium, dissolve the above white crystalline product, heat to boiling, and determine whether the reaction is complete by thin layer chromatography (TLC). The product was packed in a column of Shixijiao and separated by using an eluent of ethyl acetate: methanol = 1: 1 ratio. After purification, 1-[(4-propylpropyl-2-methoxy) phenoxy was obtained -3-[(2-methoxybenzyloxyethyl) amino-2-propanol (1-[(4-allyl-2-methoxy) phenoxy-3_ [(2-methoxy-phenoxyethyl) amino] -2 -propanol) Example 2 Synthesis of compound 3 The paper size is applicable to Chinese National Standard (CNS) A4 (210X 297 meals) 18 (Please read the precautions on the back before filling out this page}-Binding. Thread

經濟部中央標準局員工消費合作社印策 3. 環氧化合物(Epoxide)的合成;由阿魏酸加入硫酸當 觸媒,及無水乙醇後加熱沸騰,於反應完全後加入氫化鈉 水溶液調整酸蜂度:(|H)值達到中性,減壓濃縮後以甲醇再結 晶,得到4_羥基-3-甲氧基桂皮酸乙酯(4妨办〇&gt;^-3-methoxycinnamic acid ethyl ester)。將產物溶於含氫氧化鈉之 絕對乙醇溶液中’加入表氯醇(epichlorohydrine)進行反應, 俟反應完成後進行減壓濃縮,濃縮液充填於矽膠管柱,運 用己烧:乙酸乙酯為沖提液,分離獲得粗結晶。反覆以己 烷再結晶,獲得純化之4-(2,3-環氧基丙氧基)·3-甲氧基桂皮 酸乙醋。 4. 產物的合成;取4-(2,3-環氧基丙氧基&gt;3_曱氧基桂皮 酸乙S曰及2-(2-甲氧基笨氧基)乙基胺溶於無水酒精,進行反 應。混合液經減壓濃縮,濃縮液以石夕膠充填的管柱分離, 濃縮可得到白色結晶產物。再溶入氫氧化鈉之丙酮溶液, 反應完全後,運用矽膠的管柱,分離,純化後獲得(^[(i 乙氧幾基乙烯基甲氧基)苯氧基曱氧基笨氧基乙基) 胺基]-2-丙醇。 新穎之癒創木酚羥基丙醇胺化合物化合物丨〜4 ; 化合物l...(H(4-烯丙基-2·曱氧基)笨氧基_3_[(2_甲氧基苯氧 基乙基)胺基-2 丙醇(1 -[(4_aiiyUmethDxy)pheiioxyI_:3_ 本紙張尺適用中國國—家標準(CNsyM規^ -------- 7 (請先閱讀背面之注意事項再填寫本頁) )______I______.--- 、-°. .I 1^1 II— -1- ^^1.Instruction of the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 3. Synthesis of Epoxide; Ferulic acid is added as sulfuric acid as a catalyst, and anhydrous ethanol is heated to boiling. After the reaction is completed, sodium hydride aqueous solution is added to adjust the acidity : (| H) value reached neutral, concentrated under reduced pressure and recrystallized with methanol to obtain ethyl 4-hydroxy-3-methoxycinnamic acid ethyl ester (4 to do 0 &gt; ^ -3-methoxycinnamic acid ethyl ester). The product was dissolved in an absolute ethanol solution containing sodium hydroxide. 'Epichlorohydrine was added to the reaction. After the reaction was completed, the reaction solution was concentrated under reduced pressure. The concentrated solution was filled in a silica gel column. The liquid was extracted and separated to obtain crude crystals. It was recrystallized with hexane repeatedly to obtain purified 4- (2,3-epoxypropoxy) · 3-methoxycinnamate ethyl acetate. 4. Synthesis of the product; 4- (2,3-epoxypropoxy &gt; 3-methoxy cinnamic acid ethyl ester and 2- (2-methoxybenzyloxy) ethylamine were dissolved in Anhydrous alcohol was reacted. The mixed solution was concentrated under reduced pressure, and the concentrated solution was separated by a column packed with Shixi gum, and concentrated to obtain a white crystalline product. It was then dissolved in an acetone solution of sodium hydroxide. After the reaction was completed, a silica gel tube was used. Column, separated, purified (^ [(i ethoxylvinylmethoxy) phenoxyfluorenyloxybenzyloxyethyl) amino] -2-propanol. Novel guaiacol hydroxy Propanolamine Compound Compounds 丨 ~ 4; Compound l ... (H (4-allyl-2 · fluorenyl) benzyloxy_3 _ [(2-methoxyphenoxyethyl) amino group- 2 Propanol (1-[(4_aiiyUmethDxy) pheiioxyI_: 3_ This paper rule applies to China's national standard (CNsyM regulations ^ -------- 7 (Please read the precautions on the back before filling this page)) ______I______ .---,-°. .I 1 ^ 1 II— -1- ^^ 1.

五、發明説明( 經濟部中央標隼局員工消費合作社印製 取0.03莫耳N-[4-(2,3-環氧基丙氧基)_3_曱氧基苯甲基]_ 壬醯胺(N-[4-(2,3_qx&gt;xypr〇|x»^)-3-methc^benzyl]_nonanamide) 及0.09莫耳2-(2-曱氧基苯氧基)乙基胺(2_(2_V. Description of the Invention (Printed by the Consumer Cooperative of the Central Bureau of Standards, Ministry of Economic Affairs, 0.03 Molar N- [4- (2,3-epoxypropoxy) _3_fluorenylbenzyl] _ Nonamidine (N- [4- (2,3_qx &gt; xypr〇 | x »^)-3-methc ^ benzyl] _nonanamide) and 0.09 mole 2- (2-methoxyphenoxy) ethylamine (2_ (2_

Methoxyphenoxy)ethylamine)溶於無水齡睛30毫升中,室溫下 攪拌2小時’以進行胺化反應。混合液經減壓濃縮,濃縮 液以石夕膠充填的管柱分離’濃縮可得到白色結晶產物。取 適量氫氧化鈉溶於0.1%丙酮,將上述白色結晶產物溶入, 加熱至沸騰,以薄層層析片(TLC)測定是否反應完全。將產 物充填於石夕膠的管柱,運用乙酸乙酯:甲醇=1 : 1比例之 沖提液分離,純化後獲得(1-[(4-壬醯胺曱基-2-曱氧基)苯氧 基-3-[(2-甲氧基苯氧基乙基)胺基]-2-丙醇(1-[(4- nonanamidemethyl-2-methoxy)phenoxy] -3 - [(2-methoxyphenoxyethyl) amino]-2-propanol)。 實施例3 化合物2的合成 取1莫耳阿魏酸(Ferulic acid),加入少量硫酸當 觸媒,及過量無水乙醇後加熱沸騰48小時。以薄層層析片 (TLC)確定是否反應完全。反應完全後加入氫化鈉水溶液調 整酸鹼度(pH)值達到中柽,減壓濃縮後以甲醇再結晶,得 到4-經基-3-曱氧基桂皮酸乙酯(4-hydroxy-3- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 19 (請先閱讀背面之注意事項再填寫本頁) ------訂--Γ--r--線J':.--- A/ A/ ί)月 B7 五、發明説明 ; ^. 一 :;八..·丨 [(2-methoxyphenoxyethyl)amino]-2-propanol),簡稱 eugenodilol ° 化合物2.. .(H(4-乙氧羰基乙烯基-2-曱氧基)苯氧基-3-[(2-曱 氧基苯氧基乙基)胺基]-2-丙醇(1 -[(4-ethoxycarbonyl ··· ·冬·· ethenyl-2-methoxy)phenoxy]-3-[(2-metho^-phenoxyethyl) amino]-2-propanol) ° 化合物3....(l-[(4-壬醯胺甲基曱氧基)苯氧基_3-[(2-曱氧 基苯氧基乙基)胺基]-2-丙醇(1-[(4-11〇1^仙111丨(1咖6111)4-2-methoxy)phenoxy] -3 - [(2-methoxyphenoxyethyl)amino]-2-propanol),簡稱 capsinodilo卜 化合物4&quot;.(l-[(4-丙烯基-2-甲氧基)苯氧基-3-[(2-曱氧基苯氧 基乙基)胺基]-2-丙醇(l-[(4-propenyl-2-methoxy)· phenoxy]-3-[(2-methoxyphenoxyethyl)amino]-2-propanol) ,簡稱 isoeugenodilol 〇 化合物1Μ或其中間產物經再結晶後測定熔點(mp), 或再經由純化過程的產物分別測定其元素分析、質譜 (MS)、紅外線光譜(IR)、氫核磁共振光譜 CDCI3:)、紫外線吸收(ϋν)等物理化學數據可顯示該等化合 物具有明確之結構。 不同劑罝(1.0, 1.5, 3.0 mg/kg)之化合物皆可以 著下賊象,且作用時間 尽標準(CNS ) A4規格T&quot;2i〇x297公趁) 8 (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 訂---r ——,—線_| Ί!: 經濟部中央標準局員工消費合作杜印製 五、發明説明(is)———;Methoxyphenoxy) ethylamine) was dissolved in 30 ml of anhydrous eyes and stirred at room temperature for 2 hours' to carry out the amination reaction. The mixed solution was concentrated under reduced pressure, and the concentrated solution was separated and concentrated using a column packed with Shixi gum to obtain a white crystalline product. Take an appropriate amount of sodium hydroxide in 0.1% acetone, dissolve the above white crystalline product, heat to boiling, and determine whether the reaction is complete by thin layer chromatography (TLC). The product was packed in a column of Shixijiao, and the solution was separated by using an ethyl acetate: methanol = 1: 1 ratio of eluent. After purification, (1-[(4-nonylaminofluorenyl-2-fluorenyloxy)] was obtained. Phenoxy-3-[(2-methoxyphenoxyethyl) amino] -2-propanol (1-[(4- nonanamidemethyl-2-methoxy) phenoxy] -3-[(2-methoxyphenoxyethyl ) amino] -2-propanol). Example 3 Synthesis of compound 2 Take 1 mol ferulic acid, add a small amount of sulfuric acid as a catalyst, and heat and boil for 48 hours after excess ethanol. Thin layer chromatography (TLC) to determine whether the reaction is complete. After the reaction is complete, add an aqueous solution of sodium hydride to adjust the pH value to reach mid-range. After concentration under reduced pressure, recrystallize with methanol to obtain ethyl 4-mercapto-3-methoxycinnamate. (4-hydroxy-3- This paper size applies to Chinese National Standard (CNS) A4 specification (210X 297 mm) 19 (Please read the precautions on the back before filling this page) ------ Order--Γ- -r--line J ': .--- A / A / ί) month B7 V. Description of the invention; ^. A :; VIII .. · [[2-methoxyphenoxyethyl) amino] -2-propanol), abbreviated eugenodilol ° compound 2: .. (H (4-ethoxycarbonylethyl Phenyl-2-fluorenyloxy) phenoxy-3-[(2-fluorenoxyphenoxyethyl) amino] -2-propanol (1-[(4-ethoxycarbonyl ··· · winter ·· ethenyl-2-methoxy) phenoxy] -3-[(2-metho ^ -phenoxyethyl) amino] -2-propanol) ° Compound 3 .... (l-[(4-nonamidinemethylmethyloxy) Phenoxy_3-[(2-methoxyphenoxyethyl) amino] -2-propanol (1-[(4-11〇1 ^ 仙 111 丨 (1 Coffee 6111) 4-2- methoxy) phenoxy] -3-[(2-methoxyphenoxyethyl) amino] -2-propanol), abbreviated as capsinodilo compound 4 &quot;. (l-[(4-propenyl-2-methoxy) phenoxy-3- [(2-Methoxyphenoxyethyl) amino] -2-propanol (l-[(4-propenyl-2-methoxy) · phenoxy] -3-[(2-methoxyphenoxyethyl) amino] -2 -propanol), referred to as isoeugenodilol 〇 Compound 1M or its intermediate product after recrystallization to determine the melting point (mp), or the product after purification process to determine its elemental analysis, mass spectrometry (MS), infrared spectroscopy (IR), hydrogen nuclear magnetic resonance Physical and chemical data such as spectrum CDCI3 :), ultraviolet absorption (ϋν) can show that these compounds have a clear structure. Compounds with different doses of tincture (1.0, 1.5, 3.0 mg / kg) can all act on the thief, and the action time is as standard (CNS) A4 size T &quot; 2i〇x297 while taking advantage) 8 (Please read the precautions on the back before (Fill in this page) Printed by the Consumer Standards Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs --- r ——, —line _ | Ί!

------------------------------------------...J methoxycinnamic acid ethyl ester)。 取1莫耳上述產物溶於含氫氧化鈉之絕對乙醇1〇〇毫 升溶液中,於室溫之下攪拌。再加入5莫耳表氯醇 (印ichlorohydrine)於室溫下進行反應,俟反應完成後進行 減壓濃縮’濃縮液充填於破膠管柱,運用己烧:乙酸乙酯= 1 :9為沖提液,分離獲得粗結晶。反覆以己烷再結晶,獲 得純化之4-(2, 3-環氧基丙氧基)-3-甲氧基桂皮酸乙酯。 取0.03莫耳4-(2,3-環氧基丙氧基)_3_甲氧基桂皮酸乙酯 (4_(2,3_印oxypmpoxy)-3-methoxy_cinnamic acid ethyl ester)及 0.03莫耳2-(2-甲氧基苯氧基)乙基胺(2·(2_ Methoxyphenoxy)ethyl-amine)溶於無水酒精30毫升中,室溫 下攪拌2小時,以進行胺化反應。混合液經減壓濃縮,濃 縮液以矽膠充填的管柱分離,濃縮可得到白色結晶產物。 取適量氫氧化鈉溶於0.1%丙酮,將上述白色結晶產物溶 入’加熱至沸騰,以薄層層析片(TLC)測定是否反應完全。 將產物充填於矽膠的管柱,運用乙酸乙酯:曱醇=1 : 1比 例之沖提液分離’純化後獲得(1-[(4-乙氧羰基乙烯基-2-曱氧 基)苯氧基-3-[(2-曱氧基笨氧基乙基)胺基]-2-丙醇(1-[(4-ethoxycarbonylethenyl-2-methoxy)phenoxy]-3-[(2-methoxy-pheno^ethyl) amino]- 2-propanol) 0 尺度適用中國國家標準(CNS ) A4規格(210X297公釐) ~ (請先閱讀背面之注意事項再填寫本頁) —裝----訂----„---故—..1. 20------------------------------------------... J methoxycinnamic acid ethyl ester ). One mole of the above product was dissolved in 100 ml of absolute ethanol containing sodium hydroxide and stirred at room temperature. Then add 5 mol epichlorohydrin (printed ichlorohydrine) to react at room temperature. After the reaction is completed, the solution is concentrated under reduced pressure. The concentrated solution is filled in a broken tube column, and hexane: ethyl acetate = 1: 9 is used for extraction. Liquid and separated to obtain crude crystals. Recrystallization from hexane was repeated to obtain purified 4- (2,3-epoxypropoxy) -3-methoxycinnamate. Take 0.03 mole 4- (2,3-epoxypropoxy) _3_methoxy cinnamic acid ethyl ester (4_ (2,3_ 印 oxypmpoxy) -3-methoxy_cinnamic acid ethyl ester) and 0.03 mole 2 -(2-methoxyphenoxy) ethylamine (2 · (2-Methoxyphenoxy) ethyl-amine) was dissolved in 30 ml of absolute alcohol and stirred at room temperature for 2 hours to carry out the amination reaction. The mixed solution was concentrated under reduced pressure, and the concentrated solution was separated on a silica-filled column, and concentrated to obtain a white crystalline product. An appropriate amount of sodium hydroxide was dissolved in 0.1% acetone, and the white crystal product was dissolved and heated to boiling, and it was determined whether the reaction was complete by thin layer chromatography (TLC). The product was packed in a silica gel column, and was separated and purified using an ethyl acetate: methanol = 1: 1 ratio of eluent to obtain (1-[(4-ethoxycarbonylvinyl-2-fluorenyloxy) benzene. Oxy-3-[(2-methoxyoxybenzyloxyethyl) amino] -2-propanol (1-[(4-ethoxycarbonylethenyl-2-methoxy) phenoxy] -3-[(2-methoxy- pheno ^ ethyl) amino]-2-propanol) 0 scale is applicable to Chinese National Standard (CNS) A4 specification (210X297 mm) ~ (Please read the precautions on the back before filling this page) —Installation—Order-- -„--- So — .. 1. 20

經濟部中央標準局員工消費合作社印製 皆持續超過1小時;血屋方面都產生持續性的血遷下降作 用。在天竺鼠離體胸主動脈,投予10 A M去氧腎上腺素 a~Phenylephrine)產生的收縮作用,會因給予化合物 ^表2所示產生獅細,並呈現紐相_現象。在天 二鼠離體右心房及左心房,累積投予異丙基腎上腺素 (isoproterenol)可以增加右心房跳動頻率及左心房收 縮力,而化合物在濃度1〇-7,10-6及1〇、,對於異丙基 腎上腺素(lsopr〇terenol)的作用有競爭性的抑制現 象。由表3之Schild plot得知化合物在拮抗異丙基腎 上腺素(isoproterenol)對右心房的跳動頻率增加及左 心房收縮力作用上的pA2值。 本發明之化合物於添加各種賦形劑,如硬腊酸鎮、玉 米粉、澱粉、乳糖、羥酸甲基纖維素納、乙醇、甘油等, 或稀释劑(diluents)、潤滑劑&lt;iubricants)、續味劑、 崩散劑(disintegrants)、粘合劑(binders),或著色 劑、甜味劑製成錠劑或其他固形製劑,而用磷酸鹽類緩衝 液調整酸鹼度(pH)值可製成注射劑或其他液劑及各種劑 型。其中固體劑型係包括片劑、錠劑、粉末、膠囊、舌下 片、顆粒等劑型,該類劑型之組成為有效量之注射劑型、 點眼劑或各種液態投藥劑型。一般投藥劑量可隨症狀需要 而加以調配,通常為每人每次50 mg到300 mg,每天3 本紙張尺^&quot;適用中國國家標準(CNS ) A4規格(210X297公釐) * Γ ·-- ¾ - &quot; I- I - n n - - In n - 1^1 I n n - ^ I —L- II n ___I - L--h--,-1---.. €^ (請先閲讀背面之注意事項再填寫本頁) 9The printing of employee consumer cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs lasted for more than an hour; the blood house had a continuous decline in blood migration. In the guinea pig isolated thoracic aorta, administration of 10 A M phenylephrine (~ Phenylephrine) resulted in a contractile effect resulting from the administration of the compound ^ Table 2 shows the lion thin, and the phenomenon appears. In the isolated right atrium and left atrium of Tian Er mice, the cumulative administration of isoproterenol can increase the right atrial beating frequency and left atrial contractility, and the compounds are at concentrations of 10-7, 10-6, and 10. There is a competitive inhibitory effect on the action of lsoproterol. From the Schild plot in Table 3, the pA2 value of the compound on the effect of isoproterenol on the beating frequency of the right atrium and the contraction force of the left atrium was known. The compound of the present invention is added with various excipients, such as stearic acid, corn flour, starch, lactose, sodium methylcellulose, ethanol, glycerol, etc., or diluents, lubricants &lt; iubricants) , Flavor extenders, disintegrants, binders, or colorants, sweeteners to make lozenges or other solid preparations, and phosphate buffers can be made to adjust the pH value Injections or other liquids and various dosage forms. The solid dosage forms include tablets, lozenges, powders, capsules, sublingual tablets, granules and other dosage forms. The composition of this type of dosage form is an effective amount of injection dosage form, eye drop or various liquid dosage forms. The general dosage can be adjusted as the symptoms require, usually 50 mg to 300 mg per person, 3 paper rule per day ^ &quot; Applicable to China National Standard (CNS) A4 specification (210X297 mm) * Γ ·- ¾-&quot; I- I-nn--In n-1 ^ 1 I nn-^ I —L- II n ___I-L--h-,-1 --- .. € ^ (Please read the back first (Notes to fill out this page) 9

五、發明説明(+乃 二I 貪施例 4 .....-......;:::ί:'--ϋ 化合物4的合成 取等莫耳4-(2,3-環氧基甲氧基丙烯(4-(2,3-epoxypropoxy)-3-methoxy]礙|enylpropene)#f2-(2•甲氧 基苯氧基)乙基胺(2-(2-Meth(jj§|&gt;|ienoxy)ethylamine)溶於無 i J. 水酒精30毫升中’室溫下攪# Γ小時,以進行胺化反應。 混合液經減壓濃縮,濃縮液以矽膠充填的管柱分離,濃縮 可得到白色結晶產物。取適量氫氧化鈉溶於0.1%丙酮,將 上述白色結晶產物溶入,加熱至沸騰,以薄層層析片(TLC) 測定是否反應完全。將產物充填於矽膠的管柱,運用乙酸 乙酯:甲醇=1 : 1比例之沖提液分離,純化後獲得(1·[(4_ 丙烯基冬曱氧基)笨氧基-3-[(2-甲氧基苯氧基乙基)胺基]—2_ 丙 醇 (l-[(4-propenyl-2-methoxy)-phenoxy]-3-[(2_ methoxyphenoxyethyl)amino]-2-propanol) 〇 實施例5 化合物1之錠劑 讀 先 閱 讀&lt; 背V. Description of the Invention (+ 乃 二 I Corruption Example 4 .....-......; :: ί: '-ϋ The synthesis of compound 4 is equal to Mor 4- (2,3- (4- (2,3-epoxypropoxy) -3-methoxy] block | enylpropene) # f2- (2 • methoxyphenoxy) ethylamine (2- (2-Meth ( jj§ | &gt; | ienoxy) ethylamine) Dissolved in 30 ml of water-free alcohol J. Stirred at room temperature for Γ hours to carry out the amination reaction. The mixed solution was concentrated under reduced pressure, and the concentrated solution was filled with silicone gel. Separate the column and concentrate to obtain a white crystalline product. Take an appropriate amount of sodium hydroxide in 0.1% acetone, dissolve the above white crystalline product, heat to boiling, and determine whether the reaction is complete by thin layer chromatography (TLC). Fill the product In a silica gel column, an ethyl acetate: methanol = 1: 1 ratio of the eluent was used for separation, and after purification, (1 · [(4_propenyl winter alkoxy) benzyloxy-3-[(2-methyl Oxyphenoxyethyl) amino] -2-propanol (l-[(4-propenyl-2-methoxy) -phenoxy] -3-[(2-methoxyphenoxyethyl) amino] -2-propanol) 〇 Example 5 Compound 1 Tablets Read First Read

意 事 項 再 填 % X 裝 訂 線 經濟部中央標準局員工消費合作社印製 化合物1 50 mg 乳糖 30 mg 澱粉 4 mg 硬脂酸鎂 6 mg 玉米粉 10 mg 依照上述處方可製得含有化合物1之鍵劑劑型 本紙浪尺度適用中國國家標準(CNS ) A4現格( 210X297公釐 21 A7 —-----— B7 五、發明説明(8 ) 次。 藥理作用的探討 心跳、血壓作用的揮对 雄性大白鼠(Wistarstrain)重3.〇〇〜450克, 以 4〇mg/kg 苯巴比妥納(pent〇barfc)ital 皮 下注射施行麻醉’然後進行氣管切開術’並插入導管使實 驗中動物能保持呼吸順暢,亦有利於急救。在股靜脈 (femoral vein)以内徑 0.85 mm,外徑 〇.97mm 的聚 乙烯管(polyethylene tube, PE50)進行插管,以利實 驗中藥物的投予;利用三通活栓(3-way stopcock),一 端接裝有藥品的注射筒;另一端接裝有生理食鹽水的注射 筒’在給完藥物後可馬上注入些許的生理食鹽水以免藥物 滯留於聚乙烯管(PE50)管中影響實驗準確性。左股動脈也 以聚乙烯管(PE50)進行插管,同樣使用三通活栓,一端接 肝素(heparin)溶液,當聚乙烯管(PE50)管中有栓塞時可 用於疏通管路;另一端接Disposable Diaphragm Dome (TA1019),,然後接到轉訊器’經放大器,最後由記錄器記 錄藥物對大白鼠的血壓及心跳的影響。大白鼠經由股靜脈 分別投予1.0、1.5、3.0mg/k;g不同劑量的測試藥物, 探討藥物對心跳、血壓的作用。 本紙張尺度適用巾關家標準(CNs) M規格(2丨QX297公釐) 10 189.年1。 A7 五、發明説明(21) 表4 H(4-婦丙基-2-甲氧基)苯氧基-3-K2-甲氧基苯氧基乙基) 胺基-2-丙醇 (l-[(4-a%l-2-methoxy)phenoxy]-3-[(2-methoxyphenoxy ethyl) amino] -2-propanol) XH-NMR (CDC13) 6:2.93-3.16(m, 3.31-3.34(d, 3.80-3.83(m, 4.00-4.03{mf 4.13-4.19(m, 5.03-5.12(m, 5.88-6.01(m, 6.68-7.00{m, 4H, CH2-NH-CH2); 2Hf Ar-CH2); 6H, OCH3 X 2}; 2Er Ar-OCHz); 3H, Ar-OCH2CH(OH) }; 2Er -CH=CH2); 1H, -CH=CH2); mr Ar); (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印裝 MS m/s: 388 (Scan EI+). A113I. C22K29NO5/ mp. 46-48 °C · l-[(4-乙氧幾基乙烯基-2-甲氧基)苯氧基-3-[(2-甲氧基苯 氧基乙基)胺基]-2-丙醇 1 - [(4-ethoxy carbonylethenyl-2-methoxy)phenoxy] -3-[(2-meth〇5^-phenoxydhyl)amino]-2-propariol) ^-NMR (CDCI3) δ: 1·30-1·37(ια, 3H, CH3); 3.13-3.18(mr 4H, CH2-NH-CH2); 3.77-3.82(m, 6Hf OCH3X 2); 4.06-4.08(d, 2Hf Ar-OCH2); 4.15-4.19 (m, 3Hr Ar-OCH2CH(OH)); 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 23 經濟部中央標準局員工消費合作社印製 A7 _B7 五、發明説明(9 ) 結果 以苯巴比妥鈉(pentobarbital sodium)麻醉後的 正常血壓大白I’由股靜脈投予不同劑量的測試藥物,觀 察對於心跳、血壓的影響。結果如表1所示,不同劑量 (1.0, I·5, 3·0 mg/kg)化合物皆可以使心跳速率呈現 劑量相關性的顯著下降且作用時間皆持續超過i小時;血 壓方面也都產生持續性的企壓下降作用。 對天竺鼠離體jk管鬆弛作用的_任 取300_450克之天竺鼠,用力從頭部敲昏,再由頸 動脈放jk,迅速取下胸主動脈,置於冰冷的Krebs溶液 中’小心地去除血管壁周圍的脂肪結締組織,再將胸主動 脈剪成约5 mm長的環形,以兩根”己”字型的白金絲 上下固定主動脈環,置於1〇亳升通有95 %氧、5 %二 氧化兔混合氣之組織槽中,一端固定於組織槽底部,另一 知則接上力轉訊器(f〇rce transducer),經由記錄器 記錄其等長收縮(isometric contracti〇nh標本給予 1克張力,平衡60分鐘後,先給予M去氧腎上腺素 (phenylephrine)測試胸主動脈之活性,待其平衡後將去 氧腎上腺素(phenylephrine)洗去,再給予10以M去 紐H素(pher^lePhrine)使達到最大收縮,待其平衡 本紙張尺度適用巾賴¢:鄉(CNS) A4規格(21()&gt;&lt; 297公楚) —~~ -- *ίΓ·- _______---1--裝^^-----訂-- (請先閲讀背面之注意事項再填寫本頁) 11Replenishment of the matters of interest X Gutter Printing compound 1 printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs Employees' cooperatives 50 mg Lactose 30 mg Starch 4 mg Magnesium stearate 6 mg Corn flour 10 mg According to the above prescription, a bond containing Compound 1 can be prepared The dosage form of the paper is applicable to the Chinese National Standard (CNS) A4 (210X297 mm 21 A7 —----- — B7) 5. Description of the invention (8) times. Discussion of pharmacological effects Heartbeat and blood pressure effects are great for males. White rats (Wistarstrain) weighed 3.0-450 g and were anesthetized by subcutaneous injection of 40 mg / kg pentobabarfcital, followed by tracheotomy and inserted into the catheter to keep the animals in the experiment. Breathing is smooth, which is also conducive to first aid. A femoral vein is intubated with a polyethylene tube (PE50) with an inner diameter of 0.85 mm and an outer diameter of 0.97 mm to facilitate the administration of drugs in the experiment; 3-way stopcock, one end is connected with a syringe filled with medicines; the other end is connected with a syringe filled with physiological saline. 'After giving the medicine, a little physiological saline can be injected immediately to avoid the medicine. Retention in the polyethylene tube (PE50) tube affects the accuracy of the experiment. The left femoral artery is also intubated with a polyethylene tube (PE50), the same use a three-way stopcock, one end is connected to the heparin solution, when the polyethylene tube (PE50 ) When there is an embolus in the tube, it can be used to unblock the tubing; the other end is connected to the Disposable Diaphragm Dome (TA1019), and then connected to the transmitter's amplifier, and the recorder records the effect of the drug on the blood pressure and heartbeat of the rat. Rats were administered test drugs at different doses of 1.0, 1.5, and 3.0 mg / k; g through the femoral vein to explore the effects of the drugs on heartbeat and blood pressure. This paper size applies CNs M standards (2 丨 QX297) (Centi) 10 189. year 1. A7 V. Description of the invention (21) Table 4 H (4-Fopropyl-2-methoxy) phenoxy-3-K2-methoxyphenoxyethyl) amine 2-propanol (l-[(4-a% l-2-methoxy) phenoxy] -3-[(2-methoxyphenoxy ethyl) amino] -2-propanol) XH-NMR (CDC13) 6: 2.93- 3.16 (m, 3.31-3.34 (d, 3.80-3.83 (m, 4.00-4.03 (mf 4.13-4.19 (m, 5.03-5.12 (m, 5.88-6.01 (m, 6.68-7.00 {m, 4H, CH2-NH -CH2); 2Hf Ar-CH2); 6H, OCH3 X 2}; 2Er Ar-OCH z); 3H, Ar-OCH2CH (OH)}; 2Er -CH = CH2); 1H, -CH = CH2); mr Ar); (Please read the notes on the back before filling this page) Central Bureau of Standards, Ministry of Economic Affairs Employees' Cooperative Printed MS m / s: 388 (Scan EI +). A113I. C22K29NO5 / mp. 46-48 ° C · l-[(4-ethoxyquinyl-2-methoxy) phenoxy -3-[(2-methoxyphenoxyethyl) amino] -2-propanol 1-[(4-ethoxy carbonylethenyl-2-methoxy) phenoxy] -3-[(2-meth〇5 ^ -phenoxydhyl) amino] -2-propariol) ^ -NMR (CDCI3) δ: 1.30-1.37 (ια, 3H, CH3); 3.13-3.18 (mr 4H, CH2-NH-CH2); 3.77-3.82 (m, 6Hf OCH3X 2); 4.06-4.08 (d, 2Hf Ar-OCH2); 4.15-4.19 (m, 3Hr Ar-OCH2CH (OH)); This paper size applies to China National Standard (CNS) A4 (210X297) 23) A7 _B7 printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs 5. Description of the invention (9) Results Normal blood pressure Ib after normal anesthesia with pentobarbital sodium I 'was tested by femoral vein at different doses Drugs to observe the effects on heartbeat and blood pressure. The results are shown in Table 1. Compounds at different doses (1.0, 1.5, 3.0 mg / kg) can significantly reduce the heart rate in a dose-dependent manner, and the duration of action lasts longer than i hours; blood pressure also occurs. Continuous pressure to reduce pressure. For relaxation of guinea pigs in vitro, take any 300_450 grams of guinea pigs, knock them from the head with force, then put jk from the carotid artery, quickly remove the thoracic aorta, and place them in the cold Krebs solution to carefully remove the surrounding blood vessel wall Then cut the thoracic aorta into a circle of about 5 mm length, fix the aortic ring with two “H” -shaped platinum wires up and down, and place it in a 10-liter tube with 95% oxygen and 5% In the tissue trough of the rabbit dioxide mixture, one end is fixed to the bottom of the tissue trough, and the other is connected to a force transducer, and the isometric contraction is recorded via a recorder. Tension, 60 minutes after equilibration, first administer M phenylephrine to test the activity of the thoracic aorta, wash the phenylephrine after it is equilibrated, and then administer 10 phenephrine ^ lePhrine) to achieve the maximum shrinkage, wait for its balance. This paper size is suitable for towels: Countryside (CNS) A4 Specification (21 () &gt; &lt; 297 Gongchu) — ~~-* ίΓ ·-_______--- 1--install ^^ ----- order-- (Please read the notes on the back before filling Page) 11

年月曰 X-- 經濟部中夬樣隼局員工消費合作社印製 ψ'· 發明説明( 4.24-4.3lTC00CH2);6.26-6.34 (df 1H, Ar-CH=CH) 6.86-7.〇9(m, 7H, Ar);7.57-7.65 (d, 1H, Ar-CH=CH); MS m/s: 446 (Scan EI+). Anal. C24H31N07, mp. 94.6-96.4 °C .(l-[(4-壬醯胺甲基-2-甲氧基)苯氧基-3-[(2_曱氧基苯氧 基乙基)胺基]-2-丙醇(l-[(4-nonanamidemethyl- 2- methoxy) phenoxy]-3-[(2-methoxy phenoxyethyl)amino] -2-propanol) iH-NMR (CDC13) 0.80-0.92(m, 3H ,CH3); 1 · 27 (s, 10H, CH2 X 5); 1.58-1·72(m, 2H, ch2); 2.15-2.26(m, 2H, CH2); 2.78-3.11(m, 4H, ch2-nh-ch2); 3.82-3.84(m, 6H, OCH3 X 2); 3. · 98-4 · 02 (m, 2H, Ar-OCHa); 4.06-4.12(m, 3H, Ar-OCH2CH(OH) 4.34-4.37(df 2H, Ar-CH2); 5.76(br, 1H, NH) • j 6.74-6.91(m, 7H, Ar); MS m/s: 517(Scan FAB+). Anal · C29H44N2O6, mp. 138-139 °C . 本紙張尺度適用中國國家標準(CNS ) A4規格(210X29*7公釐) 24 (請先閲讀背面之注意事項再填寫本頁) 訂 線 A7 B7 五、發明説明(10) 後’給予不同濃度的測試化合物(1〇-5或1〇-6或1〇-7 Μ )’觀察不同濃度的測試化合物所造成抑制作用。 結果 在天竺鼠離體胸主動脈,投予10 β Μ去氧腎上腺素 (L-phenylephrine)產生的收縮作用,會因給予1〇_6, 1CT5及1〇-4Μ的化合物,如表2所示產生恭弛的非用-, 並呈現劑量相關的現象。 Μ泠 1 腎上腺素反應(adrenergic response) 抑制作用之掇討 (1)天竺鼠離體右心房實驗 經濟部中央標準局員工消費合作社印製 取重300〜45〇克的天竺鼠,用力敲擊頭部使其暈 厥’然後剪斷頸動脈放血’接著立即剪開胸腔,迅速將整 個心臟取出’置於室溫(20〜25。〇已通有混合氣(95% 氧、5 %二氧化碳)的Krebs溶液中’將左右房分離開 來。取自發性跳動的右心房,兩端以蛙心夾夾住,一端固 定於底部,置入充混合氣體含10亳升Krebs溶液的組織 浴器中,溫度維持在32.5 °C ’另一端則連接力量轉訊器 (force transducer),經由記錄器(COULBOURN AT-High-Speed Videograph)記錄右心房等張收縮張力 (isometric contractions )及跳動頻率。標本給予 ;紙張尺1適用〜:^國家標隼(〇^〉八4規格(210;297^釐)' ' — 12Year X—Printed by the Consumer Cooperatives of the Ministry of Economic Affairs Bureau of the People's Republic of China ψ '· Invention Description (4.24-4.3lTC00CH2); 6.26-6.34 (df 1H, Ar-CH = CH) 6.86-7.〇9 ( m, 7H, Ar); 7.57-7.65 (d, 1H, Ar-CH = CH); MS m / s: 446 (Scan EI +). Anal. C24H31N07, mp. 94.6-96.4 ° C. (l-[( 4-nonylaminomethyl-2-methoxy) phenoxy-3-[(2-methoxyphenoxyethyl) amino] -2-propanol (l-[(4-nonanamidemethyl- 2- methoxy) phenoxy] -3-[(2-methoxy phenoxyethyl) amino] -2-propanol) iH-NMR (CDC13) 0.80-0.92 (m, 3H, CH3); 1 · 27 (s, 10H, CH2 X 5); 1.58-1 · 72 (m, 2H, ch2); 2.15-2.26 (m, 2H, CH2); 2.78-3.11 (m, 4H, ch2-nh-ch2); 3.82-3.84 (m, 6H, OCH3 X 2); 3. · 98-4 · 02 (m, 2H, Ar-OCHa); 4.06-4.12 (m, 3H, Ar-OCH2CH (OH) 4.34-4.37 (df 2H, Ar-CH2); 5.76 (br, 1H, NH) • j 6.74-6.91 (m, 7H, Ar); MS m / s: 517 (Scan FAB +). Anal · C29H44N2O6, mp. 138-139 ° C. This paper standard is applicable to Chinese national standards (CNS) A4 size (210X29 * 7mm) 24 (Please read the precautions on the back before filling this page) Thread A7 B7 V. Description of the invention 10) After 'administering different concentrations of the test compound (10-5 or 10-6 or 10-7 M)', observe the inhibitory effect caused by the different concentrations of the test compound. Results In the guinea pig isolated thoracic aorta, administration The contraction effect of 10 β Μ phenylephrine (L-phenylephrine) will be caused by the administration of 10-6, 1CT5 and 10-4M compounds, as shown in Table 2 and a non-used-and shown the dose Related phenomena: ΜLING1 Adrenergic response inhibition (1) Guinea pig isolated right atrium experiment The Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs printed a guinea pig weighing 300 ~ 45 grams and knocked hard Hit the head to faint 'then cut off the carotid artery to bleed' and then immediately cut open the chest cavity and quickly remove the entire heart 'set at room temperature (20 ~ 25). 〇 The left and right chambers are separated in a Krebs solution that has been mixed with gas (95% oxygen, 5% carbon dioxide). Take the spontaneously beating right atrium, clamp both ends with a frog heart clamp, fix one end to the bottom, and place it in a tissue bath filled with a mixed gas containing 10 liters of Krebs solution, and maintain the temperature at 32.5 ° C. Connect a force transducer and record the isometric contractions and beat frequency of the right atrium through a recorder (COULBOURN AT-High-Speed Videograph). Specimen given; paper rule 1 applicable ~: ^ national standard 隼 (〇 ^> 8 4 specifications (210; 297 ^ centimeter) '' — 12

五、發明説明(Z 甲氧基)苯氧基-3-[(2-甲氧基笨氧基乙基} A7 ............................ -.. /V / w -; ,:4 ,卞B7 „..Λ /1. 、&gt; 〆一_V. Description of the invention (Z methoxy) phenoxy-3-[(2-methoxybenzyloxyethyl) A7 ... ........-.. / V / w-;,: 4, 卞 B7 „..Λ / 1., &Gt; 〆 一 _

Ά &lt;! I -一、-39195¾ (1-[(4-丙烯基-2-胺基]-2-丙醇 (1-[ (4- propenyl - 2 - methoxy) - phenoxy] -3 -[ ( 2-methoxyphenoxy ethy l)amino] -2-propanol) ^-NMRCCDCla) δ:1·11-1·25(ια, 3H, CH3); 2.87-3.12(m, 4H, CH2-NH-CH2); 3.84 (s, 6H, OCH3 X 2); 4.00- 4.14 (m, 2H, Ar-〇CH2); 4.00- 4.04 (m, 2H, Ar-OCH2); 4.13-4.16 (m, 3H, Ar-OCH2CH(OH}); 6.04-6.37 (m, 2Ef -CH=CH); 6.84-6.95 (m, 7H, Ar); MS m/s: 388 (Scan EI+) ·Ά &lt;! I-一, -39195¾ (1-[(4-propenyl-2-amino) -2-propanol (1- [(4- propenyl-2-methoxy)-phenoxy] -3-[ (2-methoxyphenoxy ethy l) amino] -2-propanol) ^ -NMRCCDCla) δ: 1.11-1 · 25 (ια, 3H, CH3); 2.87-3.12 (m, 4H, CH2-NH-CH2); 3.84 (s, 6H, OCH3 X 2); 4.00- 4.14 (m, 2H, Ar-〇CH2); 4.00- 4.04 (m, 2H, Ar-OCH2); 4.13-4.16 (m, 3H, Ar-OCH2CH ( OH}); 6.04-6.37 (m, 2Ef -CH = CH); 6.84-6.95 (m, 7H, Ar); MS m / s: 388 (Scan EI +) ·

Anal.c22H29N05, mp. 90.2-91.6 °C . !^-IL·丨丨.丨丨裝----訂丨丨丨:___丨線 {請先閲讀背面之注意事項再填寫本頁) 經濟部中央標隼局員工消費合作社印製 5 2 本紙張尺度適用中國國家標準(CNS ) A4规格(210X 297公釐) 經濟部中央標隼局員工消費合作社印製 A7 ________ B7 五、發明説明(11 ) 100〜150毫克之間的張力,待平衡後進行以下實驗: (a)累積濃度反應曲線(cumulative cone抑tration-response curves)完成 為評估測試化合物的乙型阻斷(β _bl〇ckade)活性 · · · 大小’每一個自發性跳動的離體右心房於平衡後(大约60 分鐘 &gt; ’需要分別完成兩次乙型作用劑M-ag〇nist)異 丙基腎上腺素(isoproterenol)的累積濃度曲線。實驗 設計如下:&lt;1&gt;第一次曲線直接給與異丙基腎上腺素 us〇proterenol)由低濃度到高濃度,以〇·5 1〇g單 位依次增加至達到最大反應為止;此即為對照組 。&lt;2&gt; 第 一久曲線為實驗組。先給予不同濃度的测試化合物(1〇~7 或或1〇-5 M ;由低濃度再高濃度),經作用30分 鐘後’再以異丙基腎上腺素(iS〇pr〇teren〇1)完成累積性 投藥。觀察不同濃度的測試化合物所造成的抑制作用可得 到EC5。值。 (b) pA2值的計算 根據Arunlakshana和Schild在I959年的方法,以 測試化合物濃度的對數值為橫座標,達到相同作用的作用 劑劑量比率(dose ratio)-1之對數值為縱座標,將所得 數據作圓並進行線性迴歸’可得一迴歸直線的橫座標截矩 值,即為此測試化合物的pA2值。 本紙張尺國國家標準(CNS )八槪^· ( 210X297公釐&gt; ~~~ --_ 13 (請先閲讀背面之注意事項再填寫^!^ ) -----討 線丨 . A 7 B7 五、發明説明(i2) (2)天竺鼠離體左心房實驗 由天竺鼠離體右心房實驗所得到不會自發性跳動的左 心房’於相同條件下以波笔5 rasec略大於閾值電屋 (threshold voltage)約1伏特的方形波刺激左心房引 起收縮反應。刺激頻率〇·5Ηζ ,休息張力(resting tension) 0·5克重。待平衡後(約5〇分鐘)進行以下實 驗; (a) 累積濃度反應曲線(cumulative concentration-response curves) 的完成 ,同離體右心房的實驗方 式。 (b) pA2值的計算,同離體右心房實驗的計算方法。 對/5 1 腎上腺素反應(adrenergic response) 抑制作用之結果 經濟部中央標準局員工消費合作社印製 在天竺鼠離體右心房及左心房,累積投予異丙基腎上 腺素(isoproterenol)可以增加右心房跳動頻率及左心 房收縮力’而化合物在濃度ι〇-7, 1〇-6及ict5m,可以 競性的抑制異丙基腎上腺素(isoproterenol)的作 用。接著由表3之Schild plot得知化合物在拮抗異 丙基腎上腺素(isoproterenol)對右心房的跳動頻率增 加及左心房收縮力作用上的PA2值。 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公瘦) 14 A7 B7Anal.c22H29N05, mp. 90.2-91.6 ° C.! ^-IL · 丨 丨. 丨 丨 -------- 丨 丨 丨: ___ 丨 Line {Please read the precautions on the back before filling this page) Economy Printed by the Consumer Standards Cooperative of the Ministry of Standards and Standards of the Ministry of Labor 5 2 This paper size applies to the Chinese National Standard (CNS) A4 specification (210X 297 mm) Printed by the Consumer Standards of the Central Standards of the Ministry of Economy of the Ministry of Economic Affairs A7 ______ B7 V. Description of the invention (11 ) Tension between 100 ~ 150 mg. After equilibrium, perform the following experiments: (a) Cumulative cone response-response curves are completed to evaluate the beta blocking activity of the test compound. · · · 'Each spontaneous beating of the isolated right atrium after equilibrium (approximately 60 minutes &gt;' Need to complete two separate B-agents M-agónist) isoproterenol (isoproterenol) accumulation Concentration curve. The experimental design is as follows: &lt; 1 &gt; The first curve directly gives isoproterenol (us〇proterenol) from low concentration to high concentration, increasing in order from 0.5 to 10 g units until the maximum response is reached; this is Control group. &lt; 2 &gt; The first time curve is the experimental group. Test compounds of different concentrations were first given (10-7 or 10-5 M; from low to high concentrations), and after 30 minutes of action, then isoproterenol (iSoprouteren 01 ) Complete cumulative administration. EC5 can be obtained by observing the inhibitory effects caused by different concentrations of the test compound. value. (b) Calculation of pA2 value According to the method of Arunlakshana and Schild in 1959, the logarithmic value of the concentration of the test compound is used as the horizontal coordinate, and the logarithmic value of the dose ratio-1 of the agent that achieves the same effect is taken as the vertical coordinate. The obtained data is rounded and linear regression is performed to obtain the abscissa intercept value of a regression line, that is, the pA2 value of the test compound. National paper standard (CNS) of this paper rule 槪 (((210X297 mm &gt; ~~~ --_ 13 (Please read the precautions on the back before filling in ^! ^) ----- Discussion 丨. A 7 B7 V. Description of the invention (i2) (2) Guinea pig isolated left atrium experiment The left atrium that does not spontaneously beat was obtained from the guinea pig isolated right atrium experiment. Under the same conditions, the wave pen 5 rasec is slightly larger than the threshold. (Threshold voltage) A square wave of about 1 volt stimulates the left atrium to cause a contractile response. The stimulation frequency is 0.5 · ζ and the resting tension is 0.5 grams. After the equilibrium (about 50 minutes), the following experiment is performed; (a ) The completion of cumulative concentration-response curves is the same as the experimental method of isolated right atrium. (B) The calculation of pA2 value is the same as the calculation method of isolated right atrium experiment. For / 5 1 epinephrine response ( (adrenergic response) The results of the inhibitory effect are printed on the right atrium and left atrium of guinea pigs by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs. Cumulative administration of isoproterenol can increase the right atrial beating frequency and left atrium And the compound can competitively inhibit the action of isoproterenol at concentrations ι0-7, 10-6, and ict5m. Then the Schild plot in Table 3 shows that the compound is antagonizing isopropyl The effect of adrenaline (isoproterenol) on the beating frequency of the right atrium and the contraction force of the left atrium is PA2. This paper size applies the Chinese National Standard (CNS) A4 specification (210X297 male thin) 14 A7 B7

五、發明説明(13) 經濟部中央標準局員工消費合作社印裝 ,取重300〜450克的天竺鼠,於實驗前18〜24小 時先行給予腹腔注射蛇根驗(reserpine) 5呵/fcg。將 天竺鼠擊昏後,剪斷頸動脈放血,然後立即剪開胸腔,沿 著頸部,取下氣管(長約4公分),置於室溫(約22〜 25°〇已通有混合氣(95 %氧、5 %二氧化碳)的Krebs solution培養皿中’仔細地去除周圍組織’接著將氣管 剪成每一轉有三到四個軟骨環結的螺旋形,將其等分,兩 端以蛙心夾夾住,一端固定於底部置入充混合氣含2〇毫 升Krebs溶液的組織浴器中’溫度維持在32 5艺,另 一端則連接力量轉訊器(force transducer),經由記錄 器(COULBOURN AT-High-Speed Videograph)記錄等 長收縮張力,標本給予2克的張力,待平衡後進行以下實 驗β (a)累積濃度反應曲線 實驗中氣管先平衡後(約1小時)可得到自發性張力, 然後每一等分氣管完成二次異丙基腎上腺素 (isoproterenol)的累積濃度反應曲線,其中第一次曲線 不加入測試化合物做為對照組;而第二次曲線則先加入測 15 (請先閱讀背面之注意事項再^^本頁) -----* —訂 *--»--- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) A7 B7 五、發明説明(14) 試化合物作用1小時後再進行累積濃度反應曲線;此即為 實驗組。 (b) pA2值的計算 同離體右心房實驗的計算方法。 藥物對β 2腎上腺素反應(adrenergic response) , 之結果 在得到自發性張力的天竺鼠離體氣管,累積投予異丙 基腎上腺素《isoproterenol)可以使氣管的張力產生鬆 弛的作用,化合物在濃度1(Γ6, 1〇_5及l〇-4M,可以競 ♦性的抑制異丙基腎上腺素(isoproterenol)的作用, 接著由表3之Schild plot得知,在離體氣管測試藥 物拮抗異丙基腎上腺素(isoproterenol)的鬆弛作用得 到的pA2值。 對α腎上腺素反應(adrenergic response! 抑制作用之掇討 U)累積濃度反應曲線: 同血管鬆弛的實驗,取下天竺鼠離體胸主動脈給予工 克張力’平衡60分鐘後,直接給與去氧腎上腺素(L_ phenylephrine)由低濃度到高濃度,以〇·5 i〇g單位 依次增加至達到最大反應為止;此即做為對照組。接著终 本紙張尺度適用中國國家標準(CNS )八4規格(21〇Χ297公釐) ’ 16 (請先閱讀背面之注意事項再填寫本_V. Description of the invention (13) Printed by the Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs, take guinea pigs weighing 300-450 grams and give an intraperitoneal injection of reserpine 5 h / fcg 18 to 24 hours before the experiment. After the guinea pig was stunned, the carotid artery was cut off to bleed, and then the chest cavity was immediately cut, and the trachea (about 4 cm in length) was removed along the neck, and placed at room temperature (about 22 ~ 25 °). 95% oxygen, 5% carbon dioxide) in a Krebs solution Petri dish 'carefully remove surrounding tissue'. Then cut the trachea into a spiral with three to four cartilage ring knots per revolution, divide it equally, and use a frog heart at both ends The clamp was clamped, and one end was fixed at the bottom and placed in a tissue bath filled with a mixed gas containing 20 ml of Krebs solution. The temperature was maintained at 32 ° C, and the other end was connected with a force transducer and passed through a recorder (COULBOURN). AT-High-Speed Videograph) Record the isometric contraction tension. The specimen is given a tension of 2 grams. After the balance is performed, the following experiment is performed. Β (a) Cumulative concentration response curve In the experiment, the trachea is first equilibrated (about 1 hour) to obtain spontaneous tension. Then, each aliquot of the trachea completes the secondary cumulative concentration response curve of isoproterenol. The first curve does not include the test compound as a control group; the second curve first adds the test 15 ( Please read the precautions on the back before ^^ this page) ----- * —Order *-»--- This paper size applies to China National Standard (CNS) A4 specification (210X297mm) A7 B7 V. Description of the invention (14) The cumulative concentration response curve was performed after the test compound was applied for 1 hour; this is the experimental group. (B) The calculation of pA2 value is the same as that of the right atrium experiment. The drug responds to β 2 adrenergic response. As a result, in the guinea pig isolated trachea obtained spontaneous tension, the cumulative administration of isoproterenol (isoproterenol) can relax the tension of the trachea, the compound at a concentration of 1 (Γ6, 1〇_5 and l〇- 4M can competitively inhibit the effect of isoproterenol. Then, according to the Schild plot in Table 3, it is known that pA2 obtained by antagonizing the relaxation effect of isoproterenol on the ex vivo trachea test drug. Cumulative concentration-response curve to the adrenergic response! Inhibition effect: The same as the vascular relaxation experiment, the isolated thoracic aorta of the guinea pig was removed and given a working weight of 60 grams for a balance of 60 minutes. Then, directly give L-phenylephrine from low concentration to high concentration, and increase it in order of 0.5 μg to reach the maximum response; this is used as the control group. Then the final paper size applies to China National Standard (CNS) 8 4 specifications (21〇 × 297 mm) '16 (Please read the precautions on the back before filling in this _

經濟部中央標準局員工消費合作杜印製 Μ Μ 經濟部中央標準局員工消費合作社印製 Β7 五、發明説明(if ): --;— 予不同濃度_試化合麟㈤或1〇_s或ι〇_5μ),經作 用30分鐘後,再以去氧腎上腺素(L-phenylephrine) 完成累積性投藥。觀察不同濃度酬試化合物所造成的抑 制作用可得到EC50值。 (b) pA2值的計算: 同離體右心房實驗的計算方法。 對“腎上腺素反應(adrenergic response) 抑制作用之結果 在天竺鼠離體胸主動脈,累積投予去氧腎上腺素(l_ phenylephrine)可以使血管產生收縮的作用,測試藥物 在濃度lO'lG·5及i(r4 M ’可峨爭性的抑制去氧賢 上腺素(L-phenylephrine)的作用,接著由表3之 Schild plot得知:在離體血管測試藥物拮抗去氧腎上腺 素(L-phenylephrine)的收縮作用得到的pA2值。 實施例1 化合物1的合成 -4: —phend:入:4毫 耳氫氧化鈉,於7(TC下反應1 (請先閲讀背面之注意事項再填寫本頁)Printed by the Ministry of Economic Affairs of the Central Bureau of Consumers for Du MU Μ Printed by the Consumers' Cooperative of the Central Bureau of Standards of the Ministry of Economics for printing B7 V. Invention Description (if):-; ι〇_5μ), after 30 minutes of action, then cumulative administration with phenylephrine (L-phenylephrine). EC50 values can be obtained by observing the inhibitory effects caused by test compounds at different concentrations. (b) Calculation of pA2 value: Calculation method of the right atrium experiment in vitro. As a result of the "adrenergic response" inhibitory effect, guinea pig isolated thoracic aorta, the cumulative administration of phenylephrine (l_phenylephrine) can shrink blood vessels, the test drug at a concentration of 10'lG · 5 and i (r4 M 'can suppress the effect of L-phenylephrine), and then learned from the Schild plot in Table 3: the test drug antagonizes L-phenylephrine in isolated blood vessels PA2 value obtained by the shrinkage effect of Example 1. Example 1 Synthesis of Compound-4: -phend: in: 4 mil sodium hydroxide, reacted at 7 (TC 1 (Please read the precautions on the back before filling this page )

17 經濟部中央標準局員工消費合作社印製 Γ、發明説。~~ ~~~~- 莫耳表氯醇(epicHiorohydrine),於相同條件下迴流2小時, 反應完成後減壓濃縮’其濃縮液濃縮液充填於矽膠管柱, 運用己烷:乙酸乙酯=1 : 9為沖提液,分離獲得到白色的 結晶。 &gt; . ' .¾ 取0.03莫耳3-[4_(2,3·環氧基丙氧基)_3_甲氧基]苯基丙 烯(3-[4-(2,3-epoxypropoxy)-3-methoxy]phenylpropene )及 5.0 克(0.03莫耳)2-(2-曱氧基苯氧基)乙基胺(2_(2_Meth〇xy-phenoxy)ethylamine)溶於無水酒精3〇毫升中,室溫下攪拌2 小時,以進行胺化反應。混合液經減壓濃縮,濃縮液以矽 膠充填的管柱分離’濃縮可得到白色結晶產物。取適量氫 氧化納溶於0.1%丙嗣,將上述白色結晶產物溶入,加熱至 沸騰,以薄層層析片(TLC)測定是否反應完全。將產物充填 於石夕膠的管柱,運用乙酸乙酯:甲醇=1 : 1比例之沖提液 分離,純化後獲得1-[(4-婦丙基-2-曱氧基)苯氧基-3-[(2-甲氧 基本氧基乙基)胺基-2-丙醇(1 -[(4-allyl-2-methoxy)phenoxy-3_ [(2-methoxy-phenoxyethyl)amino]-2-propanol) 實施例2 化合物3的合成 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公餐) 18 (請先閏讀背面之注意事項再填寫本頁} -裝. 訂 線17 Printed by the Consumer Cooperatives of the Central Bureau of Standards, Ministry of Economic Affairs Γ, Invention. ~~ ~~~~-EpicHiorohydrine was refluxed under the same conditions for 2 hours. After the reaction was completed, the solution was concentrated under reduced pressure. The concentrated solution was filled in a silica gel column, and hexane: ethyl acetate = 1: 9 is the eluent, and white crystals are obtained by separation. &gt;. '.¾ Take 0.03 mole 3- [4_ (2,3 · epoxypropoxy) _3_methoxy] phenylpropene (3- [4- (2,3-epoxypropoxy) -3 -methoxy] phenylpropene) and 5.0 g (0.03 mole) of 2- (2-methoxyoxyphenoxy) ethylamine (2_ (2_Meth〇xy-phenoxy) ethylamine) dissolved in 30 ml of absolute alcohol at room temperature Stir for 2 hours to carry out the amination reaction. The mixed solution was concentrated under reduced pressure, and the concentrated solution was separated and concentrated using a silica-filled column to obtain a white crystalline product. Take an appropriate amount of sodium hydroxide and dissolve it in 0.1% propidium, dissolve the above white crystalline product, heat to boiling, and determine whether the reaction is complete by thin layer chromatography (TLC). The product was packed in a column of Shixijiao and separated by using an eluent of ethyl acetate: methanol = 1: 1 ratio. After purification, 1-[(4-propylpropyl-2-methoxy) phenoxy was obtained -3-[(2-methoxybenzyloxyethyl) amino-2-propanol (1-[(4-allyl-2-methoxy) phenoxy-3_ [(2-methoxy-phenoxyethyl) amino] -2 -propanol) Example 2 Synthesis of compound 3 The paper size is applicable to Chinese National Standard (CNS) A4 (210X 297 meals) 18 (Please read the precautions on the back before filling out this page}-Binding. Thread

五、發明説明( 經濟部中央標隼局員工消費合作社印製 取0.03莫耳N-[4-(2,3-環氧基丙氧基)_3_曱氧基苯甲基]_ 壬醯胺(N-[4-(2,3_qx&gt;xypr〇|x»^)-3-methc^benzyl]_nonanamide) 及0.09莫耳2-(2-曱氧基苯氧基)乙基胺(2_(2_V. Description of the Invention (Printed by the Consumer Cooperative of the Central Bureau of Standards, Ministry of Economic Affairs, 0.03 Molar N- [4- (2,3-epoxypropoxy) _3_fluorenylbenzyl] _ Nonamidine (N- [4- (2,3_qx &gt; xypr〇 | x »^)-3-methc ^ benzyl] _nonanamide) and 0.09 mole 2- (2-methoxyphenoxy) ethylamine (2_ (2_

Methoxyphenoxy)ethylamine)溶於無水齡睛30毫升中,室溫下 攪拌2小時’以進行胺化反應。混合液經減壓濃縮,濃縮 液以石夕膠充填的管柱分離’濃縮可得到白色結晶產物。取 適量氫氧化鈉溶於0.1%丙酮,將上述白色結晶產物溶入, 加熱至沸騰,以薄層層析片(TLC)測定是否反應完全。將產 物充填於石夕膠的管柱,運用乙酸乙酯:甲醇=1 : 1比例之 沖提液分離,純化後獲得(1-[(4-壬醯胺曱基-2-曱氧基)苯氧 基-3-[(2-甲氧基苯氧基乙基)胺基]-2-丙醇(1-[(4- nonanamidemethyl-2-methoxy)phenoxy] -3 - [(2-methoxyphenoxyethyl) amino]-2-propanol)。 實施例3 化合物2的合成 取1莫耳阿魏酸(Ferulic acid),加入少量硫酸當 觸媒,及過量無水乙醇後加熱沸騰48小時。以薄層層析片 (TLC)確定是否反應完全。反應完全後加入氫化鈉水溶液調 整酸鹼度(pH)值達到中柽,減壓濃縮後以甲醇再結晶,得 到4-經基-3-曱氧基桂皮酸乙酯(4-hydroxy-3- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 19 (請先閱讀背面之注意事項再填寫本頁) ------訂--Γ--r--線J':.--- 經濟部中央標準局員工消費合作杜印製 五、發明説明(is)———;Methoxyphenoxy) ethylamine) was dissolved in 30 ml of anhydrous eyes and stirred at room temperature for 2 hours' to carry out the amination reaction. The mixed solution was concentrated under reduced pressure, and the concentrated solution was separated and concentrated using a column packed with Shixi gum to obtain a white crystalline product. Take an appropriate amount of sodium hydroxide in 0.1% acetone, dissolve the above white crystalline product, heat to boiling, and determine whether the reaction is complete by thin layer chromatography (TLC). The product was packed in a column of Shixijiao, and the solution was separated by using an ethyl acetate: methanol = 1: 1 ratio of eluent. After purification, (1-[(4-nonylaminofluorenyl-2-fluorenyloxy)] was obtained. Phenoxy-3-[(2-methoxyphenoxyethyl) amino] -2-propanol (1-[(4- nonanamidemethyl-2-methoxy) phenoxy] -3-[(2-methoxyphenoxyethyl ) amino] -2-propanol). Example 3 Synthesis of compound 2 Take 1 mol ferulic acid, add a small amount of sulfuric acid as a catalyst, and heat and boil for 48 hours after excess ethanol. Thin layer chromatography (TLC) to determine whether the reaction is complete. After the reaction is complete, add an aqueous solution of sodium hydride to adjust the pH value to reach mid-range. After concentration under reduced pressure, recrystallize with methanol to obtain ethyl 4-mercapto-3-methoxycinnamate. (4-hydroxy-3- This paper size applies to Chinese National Standard (CNS) A4 specification (210X 297 mm) 19 (Please read the precautions on the back before filling this page) ------ Order--Γ- -r--line J ': .--- Consumption cooperation between employees of the Central Bureau of Standards of the Ministry of Economic Affairs.

------------------------------------------...J methoxycinnamic acid ethyl ester)。 取1莫耳上述產物溶於含氫氧化鈉之絕對乙醇1〇〇毫 升溶液中,於室溫之下攪拌。再加入5莫耳表氯醇 (印ichlorohydrine)於室溫下進行反應,俟反應完成後進行 減壓濃縮’濃縮液充填於破膠管柱,運用己烧:乙酸乙酯= 1 :9為沖提液,分離獲得粗結晶。反覆以己烷再結晶,獲 得純化之4-(2, 3-環氧基丙氧基)-3-甲氧基桂皮酸乙酯。 取0.03莫耳4-(2,3-環氧基丙氧基)_3_甲氧基桂皮酸乙酯 (4_(2,3_印oxypmpoxy)-3-methoxy_cinnamic acid ethyl ester)及 0.03莫耳2-(2-甲氧基苯氧基)乙基胺(2·(2_ Methoxyphenoxy)ethyl-amine)溶於無水酒精30毫升中,室溫 下攪拌2小時,以進行胺化反應。混合液經減壓濃縮,濃 縮液以矽膠充填的管柱分離,濃縮可得到白色結晶產物。 取適量氫氧化鈉溶於0.1%丙酮,將上述白色結晶產物溶 入’加熱至沸騰,以薄層層析片(TLC)測定是否反應完全。 將產物充填於矽膠的管柱,運用乙酸乙酯:曱醇=1 : 1比 例之沖提液分離’純化後獲得(1-[(4-乙氧羰基乙烯基-2-曱氧 基)苯氧基-3-[(2-曱氧基笨氧基乙基)胺基]-2-丙醇(1-[(4-ethoxycarbonylethenyl-2-methoxy)phenoxy]-3-[(2-methoxy-pheno^ethyl) amino]- 2-propanol) 0 尺度適用中國國家標準(CNS ) A4規格(210X297公釐) ~ (請先閱讀背面之注意事項再填寫本頁) —裝----訂----„---故—..1. 20------------------------------------------... J methoxycinnamic acid ethyl ester ). One mole of the above product was dissolved in 100 ml of absolute ethanol containing sodium hydroxide and stirred at room temperature. Then add 5 mol epichlorohydrin (printed ichlorohydrine) to react at room temperature. After the reaction is completed, the solution is concentrated under reduced pressure. The concentrated solution is filled in a broken tube column, and hexane: ethyl acetate = 1: 9 is used for extraction. Liquid and separated to obtain crude crystals. Recrystallization from hexane was repeated to obtain purified 4- (2,3-epoxypropoxy) -3-methoxycinnamate. Take 0.03 mole 4- (2,3-epoxypropoxy) _3_methoxy cinnamic acid ethyl ester (4_ (2,3_ 印 oxypmpoxy) -3-methoxy_cinnamic acid ethyl ester) and 0.03 mole 2 -(2-methoxyphenoxy) ethylamine (2 · (2-Methoxyphenoxy) ethyl-amine) was dissolved in 30 ml of absolute alcohol and stirred at room temperature for 2 hours to carry out the amination reaction. The mixed solution was concentrated under reduced pressure, and the concentrated solution was separated on a silica-filled column, and concentrated to obtain a white crystalline product. An appropriate amount of sodium hydroxide was dissolved in 0.1% acetone, and the white crystal product was dissolved and heated to boiling, and it was determined whether the reaction was complete by thin layer chromatography (TLC). The product was packed in a silica gel column, and was separated and purified using an ethyl acetate: methanol = 1: 1 ratio of eluent to obtain (1-[(4-ethoxycarbonylvinyl-2-fluorenyloxy) benzene. Oxy-3-[(2-methoxyoxybenzyloxyethyl) amino] -2-propanol (1-[(4-ethoxycarbonylethenyl-2-methoxy) phenoxy] -3-[(2-methoxy- pheno ^ ethyl) amino]-2-propanol) 0 scale is applicable to Chinese National Standard (CNS) A4 specification (210X297 mm) ~ (Please read the precautions on the back before filling this page) —Installation—Order-- -„--- So — .. 1. 20

五、發明説明(+乃 二I 貪施例 4 .....-......;:::ί:'--ϋ 化合物4的合成 取等莫耳4-(2,3-環氧基甲氧基丙烯(4-(2,3-epoxypropoxy)-3-methoxy]礙|enylpropene)#f2-(2•甲氧 基苯氧基)乙基胺(2-(2-Meth(jj§|&gt;|ienoxy)ethylamine)溶於無 i J. 水酒精30毫升中’室溫下攪# Γ小時,以進行胺化反應。 混合液經減壓濃縮,濃縮液以矽膠充填的管柱分離,濃縮 可得到白色結晶產物。取適量氫氧化鈉溶於0.1%丙酮,將 上述白色結晶產物溶入,加熱至沸騰,以薄層層析片(TLC) 測定是否反應完全。將產物充填於矽膠的管柱,運用乙酸 乙酯:甲醇=1 : 1比例之沖提液分離,純化後獲得(1·[(4_ 丙烯基冬曱氧基)笨氧基-3-[(2-甲氧基苯氧基乙基)胺基]—2_ 丙 醇 (l-[(4-propenyl-2-methoxy)-phenoxy]-3-[(2_ methoxyphenoxyethyl)amino]-2-propanol) 〇 實施例5 化合物1之錠劑 讀 先 閱 讀&lt; 背V. Description of the Invention (+ 乃 二 I Corruption Example 4 .....-......; :: ί: '-ϋ The synthesis of compound 4 is equal to Mor 4- (2,3- (4- (2,3-epoxypropoxy) -3-methoxy] block | enylpropene) # f2- (2 • methoxyphenoxy) ethylamine (2- (2-Meth ( jj§ | &gt; | ienoxy) ethylamine) Dissolved in 30 ml of water-free alcohol J. Stirred at room temperature for Γ hours to carry out the amination reaction. The mixed solution was concentrated under reduced pressure, and the concentrated solution was filled with silicone gel. Separate the column and concentrate to obtain a white crystalline product. Take an appropriate amount of sodium hydroxide in 0.1% acetone, dissolve the above white crystalline product, heat to boiling, and determine whether the reaction is complete by thin layer chromatography (TLC). Fill the product In a silica gel column, an ethyl acetate: methanol = 1: 1 ratio of the eluent was used for separation, and after purification, (1 · [(4_propenyl winter alkoxy) benzyloxy-3-[(2-methyl Oxyphenoxyethyl) amino] -2-propanol (l-[(4-propenyl-2-methoxy) -phenoxy] -3-[(2-methoxyphenoxyethyl) amino] -2-propanol) 〇 Example 5 Compound 1 Tablets Read First Read

意 事 項 再 填 % X 裝 訂 線 經濟部中央標準局員工消費合作社印製 化合物1 50 mg 乳糖 30 mg 澱粉 4 mg 硬脂酸鎂 6 mg 玉米粉 10 mg 依照上述處方可製得含有化合物1之鍵劑劑型 本紙浪尺度適用中國國家標準(CNS ) A4現格( 210X297公釐 21Replenishment of the matters of interest X Gutter Printing compound 1 printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs Employees' cooperatives 50 mg Lactose 30 mg Starch 4 mg Magnesium stearate 6 mg Corn flour 10 mg According to the above prescription, a bond containing Compound 1 can be prepared The dosage form of this paper is applicable to the Chinese National Standard (CNS) A4, and it is 210X297 mm 21

7 7 · A B 五、發明説明(?竣) ' 血麼改變值 (mmHg) 劑量 1 mg/kg 1.5 mg/kg 3 mg/kg 1 -23.1 ± 4.5 -30.1 ± 3_6 •38.1 ± 5.1 2 -37.5 ± 5.2 -44.2 ± 8.0 -52_4 ± 4·5 3 -32.6 ± 5.5 -41.7 ± 4.0 -52.0 ± 8.0 4 -24.9 ± 3.2 -29.5 ± 5.1 -36.4 ± 7.2 (請先Μ讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 表 2 表 3 值 * 化合物 βι 右心房/左心房 β2 α / 1 7.83/7.95 6.59 8.12 2 8.02/8.16 7.05 7.95 3 7.80/7.61 -6.81 7.12 4 7.63/7.89 6.13 7.20 ΙΟ^Μ ι〇·5μ ΙΟ^Μ 1 -62.8 ± 8.71 -51.7 ± 6.8 -39.7 ± 9.1 2 •56.7 ± 5.1 -42.1 ± 9.1 -35.9 ± 7.9 3 -55.1 ± 7.4 -40.7 ± 8.4 -34.5 ± 4.2 4 -38:1 ± 6.5 -30.1 ± 3.6 -23.4 ± 3.7. 本紙張尺度適用中國國家標华(CNS ) A4規格(210X 297公釐) 22 189.年1。 A7 五、發明説明(21) 表4 H(4-婦丙基-2-甲氧基)苯氧基-3-K2-甲氧基苯氧基乙基) 胺基-2-丙醇 (l-[(4-a%l-2-methoxy)phenoxy]-3-[(2-methoxyphenoxy ethyl) amino] -2-propanol) XH-NMR (CDC13) 6:2.93-3.16(m, 3.31-3.34(d, 3.80-3.83(m, 4.00-4.03{mf 4.13-4.19(m, 5.03-5.12(m, 5.88-6.01(m, 6.68-7.00{m, 4H, CH2-NH-CH2); 2Hf Ar-CH2); 6H, OCH3 X 2}; 2Er Ar-OCHz); 3H, Ar-OCH2CH(OH) }; 2Er -CH=CH2); 1H, -CH=CH2); mr Ar); (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印裝 MS m/s: 388 (Scan EI+). A113I. C22K29NO5/ mp. 46-48 °C · l-[(4-乙氧幾基乙烯基-2-甲氧基)苯氧基-3-[(2-甲氧基苯 氧基乙基)胺基]-2-丙醇 1 - [(4-ethoxy carbonylethenyl-2-methoxy)phenoxy] -3-[(2-meth〇5^-phenoxydhyl)amino]-2-propariol) ^-NMR (CDCI3) δ: 1·30-1·37(ια, 3H, CH3); 3.13-3.18(mr 4H, CH2-NH-CH2); 3.77-3.82(m, 6Hf OCH3X 2); 4.06-4.08(d, 2Hf Ar-OCH2); 4.15-4.19 (m, 3Hr Ar-OCH2CH(OH)); 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 237 7 · AB V. Description of the invention (? Completed) 'Change in blood (mmHg) Dose 1 mg / kg 1.5 mg / kg 3 mg / kg 1 -23.1 ± 4.5 -30.1 ± 3_6 • 38.1 ± 5.1 2 -37.5 ± 5.2 -44.2 ± 8.0 -52_4 ± 4.55 3 -32.6 ± 5.5 -41.7 ± 4.0 -52.0 ± 8.0 4 -24.9 ± 3.2 -29.5 ± 5.1 -36.4 ± 7.2 (Please read the precautions on the back before filling this page ) Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs. 6.13 7.20 ΙΟ ^ Μ ι〇 · 5μ ΙΟ ^ Μ 1 -62.8 ± 8.71 -51.7 ± 6.8 -39.7 ± 9.1 2 • 56.7 ± 5.1 -42.1 ± 9.1 -35.9 ± 7.9 3 -55.1 ± 7.4 -40.7 ± 8.4 -34.5 ± 4.2 4 -38: 1 ± 6.5 -30.1 ± 3.6 -23.4 ± 3.7. This paper size is applicable to China National Standard (CNS) A4 specification (210X 297 mm) 22 189.year 1. A7 V. Description of the invention (21) Table 4 H (4-Fopropyl-2-methoxy) phenoxy-3-K2-methoxyphenoxyethyl) amino-2-propanol (l -[(4-a% l-2-methoxy) phenoxy] -3-[(2-methoxyphenoxy ethyl) amino] -2-propanol) XH-NMR (CDC13) 6: 2.93-3.16 (m, 3.31-3.34 ( d, 3.80-3.83 (m, 4.00-4.03 {mf 4.13-4.19 (m, 5.03-5.12 (m, 5.88-6.01 (m, 6.68-7.00 {m, 4H, CH2-NH-CH2)); 2Hf Ar-CH2 ); 6H, OCH3 X 2}; 2Er Ar-OCHz); 3H, Ar-OCH2CH (OH)}; 2Er -CH = CH2); 1H, -CH = CH2); mr Ar); Please fill out this page again) MS MS / s: 388 (Scan EI +). A113I. C22K29NO5 / mp. 46-48 ° C · l-[(4-ethoxyquinyl Vinyl-2-methoxy) phenoxy-3-[(2-methoxyphenoxyethyl) amino] -2-propanol 1-[(4-ethoxy carbonylethenyl-2-methoxy) phenoxy ] -3-[(2-meth〇5 ^ -phenoxydhyl) amino] -2-propariol) ^ -NMR (CDCI3) δ: 1.30-1 · 37 (ια, 3H, CH3); 3.13-3.18 (mr 4H, CH2-NH-CH2); 3.77-3.82 (m, 6Hf OCH3X 2); 4.06-4.08 (d, 2Hf Ar-OCH2); 4.15-4.19 (m, 3Hr Ar-OCH2CH (OH)); Size of this paper Be applicable China National Standard (CNS) A4 Specification (210X297 mm) 23

年月曰 X-- 經濟部中夬樣隼局員工消費合作社印製 ψ'· 發明説明( 4.24-4.3lTC00CH2);6.26-6.34 (df 1H, Ar-CH=CH) 6.86-7.〇9(m, 7H, Ar);7.57-7.65 (d, 1H, Ar-CH=CH); MS m/s: 446 (Scan EI+). Anal. C24H31N07, mp. 94.6-96.4 °C .(l-[(4-壬醯胺甲基-2-甲氧基)苯氧基-3-[(2_曱氧基苯氧 基乙基)胺基]-2-丙醇(l-[(4-nonanamidemethyl- 2- methoxy) phenoxy]-3-[(2-methoxy phenoxyethyl)amino] -2-propanol) iH-NMR (CDC13) 0.80-0.92(m, 3H ,CH3); 1 · 27 (s, 10H, CH2 X 5); 1.58-1·72(m, 2H, ch2); 2.15-2.26(m, 2H, CH2); 2.78-3.11(m, 4H, ch2-nh-ch2); 3.82-3.84(m, 6H, OCH3 X 2); 3. · 98-4 · 02 (m, 2H, Ar-OCHa); 4.06-4.12(m, 3H, Ar-OCH2CH(OH) 4.34-4.37(df 2H, Ar-CH2); 5.76(br, 1H, NH) • j 6.74-6.91(m, 7H, Ar); MS m/s: 517(Scan FAB+). Anal · C29H44N2O6, mp. 138-139 °C . 本紙張尺度適用中國國家標準(CNS ) A4規格(210X29*7公釐) 24 (請先閲讀背面之注意事項再填寫本頁) 訂 線Year X—Printed by the Consumer Cooperatives of the Ministry of Economic Affairs Bureau of the People's Republic of China ψ '· Invention Description (4.24-4.3lTC00CH2); 6.26-6.34 (df 1H, Ar-CH = CH) 6.86-7.〇9 ( m, 7H, Ar); 7.57-7.65 (d, 1H, Ar-CH = CH); MS m / s: 446 (Scan EI +). Anal. C24H31N07, mp. 94.6-96.4 ° C. (l-[( 4-nonylaminomethyl-2-methoxy) phenoxy-3-[(2-methoxyphenoxyethyl) amino] -2-propanol (l-[(4-nonanamidemethyl- 2- methoxy) phenoxy] -3-[(2-methoxy phenoxyethyl) amino] -2-propanol) iH-NMR (CDC13) 0.80-0.92 (m, 3H, CH3); 1 · 27 (s, 10H, CH2 X 5); 1.58-1 · 72 (m, 2H, ch2); 2.15-2.26 (m, 2H, CH2); 2.78-3.11 (m, 4H, ch2-nh-ch2); 3.82-3.84 (m, 6H, OCH3 X 2); 3. · 98-4 · 02 (m, 2H, Ar-OCHa); 4.06-4.12 (m, 3H, Ar-OCH2CH (OH) 4.34-4.37 (df 2H, Ar-CH2); 5.76 (br, 1H, NH) • j 6.74-6.91 (m, 7H, Ar); MS m / s: 517 (Scan FAB +). Anal · C29H44N2O6, mp. 138-139 ° C. This paper standard is applicable to Chinese national standards (CNS) A4 size (210X29 * 7mm) 24 (Please read the precautions on the back before filling this page)

五、發明説明(Z 甲氧基)苯氧基-3-[(2-甲氧基笨氧基乙基} A7 ............................ -.. /V / w -; ,:4 ,卞B7 „..Λ /1. 、&gt; 〆一_V. Description of the invention (Z methoxy) phenoxy-3-[(2-methoxybenzyloxyethyl) A7 ... ........-.. / V / w-;,: 4, 卞 B7 „..Λ / 1., &Gt; 〆 一 _

Ά &lt;! I -一、-39195¾ (1-[(4-丙烯基-2-胺基]-2-丙醇 (1-[ (4- propenyl - 2 - methoxy) - phenoxy] -3 -[ ( 2-methoxyphenoxy ethy l)amino] -2-propanol) ^-NMRCCDCla) δ:1·11-1·25(ια, 3H, CH3); 2.87-3.12(m, 4H, CH2-NH-CH2); 3.84 (s, 6H, OCH3 X 2); 4.00- 4.14 (m, 2H, Ar-〇CH2); 4.00- 4.04 (m, 2H, Ar-OCH2); 4.13-4.16 (m, 3H, Ar-OCH2CH(OH}); 6.04-6.37 (m, 2Ef -CH=CH); 6.84-6.95 (m, 7H, Ar); MS m/s: 388 (Scan EI+) ·Ά &lt;! I-一, -39195¾ (1-[(4-propenyl-2-amino) -2-propanol (1- [(4- propenyl-2-methoxy)-phenoxy] -3-[ (2-methoxyphenoxy ethy l) amino] -2-propanol) ^ -NMRCCDCla) δ: 1.11-1 · 25 (ια, 3H, CH3); 2.87-3.12 (m, 4H, CH2-NH-CH2); 3.84 (s, 6H, OCH3 X 2); 4.00- 4.14 (m, 2H, Ar-〇CH2); 4.00- 4.04 (m, 2H, Ar-OCH2); 4.13-4.16 (m, 3H, Ar-OCH2CH ( OH}); 6.04-6.37 (m, 2Ef -CH = CH); 6.84-6.95 (m, 7H, Ar); MS m / s: 388 (Scan EI +) ·

Anal.c22H29N05, mp. 90.2-91.6 °C . !^-IL·丨丨.丨丨裝----訂丨丨丨:___丨線 {請先閲讀背面之注意事項再填寫本頁) 經濟部中央標隼局員工消費合作社印製 5 2 本紙張尺度適用中國國家標準(CNS ) A4规格(210X 297公釐)Anal.c22H29N05, mp. 90.2-91.6 ° C.! ^-IL · 丨 丨. 丨 丨 -------- 丨 丨 丨: ___ 丨 Line {Please read the precautions on the back before filling this page) Economy Printed by the Consumer Standards Cooperative of the Ministry of Standards and Standards of the Ministry of Foreign Affairs of the People's Republic of China 5 2 This paper size applies to China National Standard (CNS) A4 (210X 297 mm)

Claims (1)

Λ% Α8 Β8 C8 D8 申請專利範圍..................................... 1· 一種化合物,(H(4-乙氧羰基乙烯基·2#氧基)苯氧基 各[(2-甲氧基苯氧基乙基)胺棊碎丙醇(ΐ-[(4-ethoxycarbonyLethenyl-2-meth〇5iy) phenoxy]-3-[(2-mdhQ^-pJi^c^ethyL)ainin(^-2-propanol) 〇 • &quot; -V;.' 2· —種化合物,1屯4·烯丙基甲氧基)苯氧基_3·[(2-甲氧 基苯氧基乙基)胺棊-2 -丙醇([ (4-allyl-2-methoxy) phenoxy - 3- 2 [ (2- methoxy - phenoxyethyl) amino]-2- propanol) ° 3. —種也金物,(irK4-壬醯胺f基4▼氧基)苯氧基-3_ 1(2-甲氧基苯氧基乙基)胺基]-2-杨醇l-[(4-nona她riide-2-methoxy)phenoXy] -3 -{(2-methoxypheno^ethyl)amino]-2_propanol)。 4. 一種化合物,(1-K4-爲烯基_2-甲氧基)苯氧基-HQ-甲 氧基苯氡基心基)骇基Jr 2 -两醇(1 r[(4-propenyl-2-methj〇xy)-phenoxy]-3-[(2-methoxyphetioxyethyl)amino]-_ 2-propanol)。 5. -·種合成申請專利範圍第.1項化合物之方法,其係包 括; (1)環氧化合物(Epoxide)的合成;由阿魏廉加入琉酸 當墙媒,及無水乙醇後加熱沸騰,於反應完全後加入氫 化鈉水溶液調整酸鹼度(pH)值達到中性,減壓濃縮後以_ 甲篇再結晶,得到4-羥基-3-甲氧基桂皮酸乙酯(4-hydroxy-3-methoxycinnamic acid ethyl pster) 〇 將產物溶於 含氫氧化鈉之絕對乙醇溶液中,加入表氯醇 (epichlorohydrine)進行反應,俟反應完成後進行減壓濃.. .縮,濃縮液充填於石夕膠管柱,運用己烷:乙酸旨為沖 提液.,分離獲獲粗結晶。反覆以己烷再結晶,獲得純化 之4&gt;(2,3-環氧基丙氧基)·3-甲氧基桂皮酸乙酯,· (請先聞讀背面之注意事項再填寫本頁) 訂 經濟部中央標隼局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) 26 Λ% Α8 Β8 C8 D8 申請專利範圍..................................... 1· 一種化合物,(H(4-乙氧羰基乙烯基·2#氧基)苯氧基 各[(2-甲氧基苯氧基乙基)胺棊碎丙醇(ΐ-[(4-ethoxycarbonyLethenyl-2-meth〇5iy) phenoxy]-3-[(2-mdhQ^-pJi^c^ethyL)ainin(^-2-propanol) 〇 • &quot; -V;.' 2· —種化合物,1屯4·烯丙基甲氧基)苯氧基_3·[(2-甲氧 基苯氧基乙基)胺棊-2 -丙醇([ (4-allyl-2-methoxy) phenoxy - 3- 2 [ (2- methoxy - phenoxyethyl) amino]-2- propanol) ° 3. —種也金物,(irK4-壬醯胺f基4▼氧基)苯氧基-3_ 1(2-甲氧基苯氧基乙基)胺基]-2-杨醇l-[(4-nona她riide-2-methoxy)phenoXy] -3 -{(2-methoxypheno^ethyl)amino]-2_propanol)。 4. 一種化合物,(1-K4-爲烯基_2-甲氧基)苯氧基-HQ-甲 氧基苯氡基心基)骇基Jr 2 -两醇(1 r[(4-propenyl-2-methj〇xy)-phenoxy]-3-[(2-methoxyphetioxyethyl)amino]-_ 2-propanol)。 5. -·種合成申請專利範圍第.1項化合物之方法,其係包 括; (1)環氧化合物(Epoxide)的合成;由阿魏廉加入琉酸 當墙媒,及無水乙醇後加熱沸騰,於反應完全後加入氫 化鈉水溶液調整酸鹼度(pH)值達到中性,減壓濃縮後以_ 甲篇再結晶,得到4-羥基-3-甲氧基桂皮酸乙酯(4-hydroxy-3-methoxycinnamic acid ethyl pster) 〇 將產物溶於 含氫氧化鈉之絕對乙醇溶液中,加入表氯醇 (epichlorohydrine)進行反應,俟反應完成後進行減壓濃.. .縮,濃縮液充填於石夕膠管柱,運用己烷:乙酸旨為沖 提液.,分離獲獲粗結晶。反覆以己烷再結晶,獲得純化 之4&gt;(2,3-環氧基丙氧基)·3-甲氧基桂皮酸乙酯,· (請先聞讀背面之注意事項再填寫本頁) 訂 經濟部中央標隼局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) 26 Α8 Β8 C8 D8 S91952 六、申請專利範圍 (2)產物的合成;取4-(2,3-環氧基丙氧基)-3-甲氧基丨 桂皮酸乙酯幕2_ (2-甲氧上苯氧基)乙基胺溶於無水酒 精,進行反應.。混合液鐵減壓濃縮,濃縮液以矽膠充 填的管柱分離’濃縮可樣到白色結晶產物^再溶入氣 氧(匕鈉之丙酮溶液,反應完全後,運用石夕膠的管枉, 分麵,純化後獲得(14(4—乙氧羰基乙烯基-2-曱氧基)苯 氧基-HO甲氧基笨氣基乙基)胺基]_2_丙醇。 6. —雇具有a/腎上腺素激性阻斷劑活性之藥學組合 物’其係以申請專利範圍第1項化合物作為主成份並 添加各種賦形劑。 7. —種具有α//5-腎上膝素激性阻斷锹活性之藥學组合 物’其係以申請專利範圍第2項化合物作為主成份敢 ~添加|種賦帑劑。 (請先閲讀背面之注意事項再填寫本頁) Ε α係 各 会 Α 主_ 藥為 之作 涂合 劑化 斷項 胜3 陡第 务範 腺利ift i 經濟部中央標準局員工消費合作社印製 合成 組主 學為 藥作之咖 性合务化 劑項 斷4; 孤第 像圍 激m卜 倉利劑 ^-奉形 腎申種 3-以各 β係^ α其添 有,J1· 具物份 本紙張尺度適用中國國 (CNS ) A4規格(210X297公釐) 27Λ% Α8 Β8 C8 D8 Scope of patent application ... , (H (4-ethoxycarbonylvinyl · 2 # oxy) phenoxy, each [(2-methoxyphenoxyethyl) amine, mashed propanol (ΐ-[(4-ethoxycarbonyLethenyl-2- meth〇5iy) phenoxy] -3-[(2-mdhQ ^ -pJi ^ c ^ ethyL) ainin (^-2-propanol) 〇 &quot;-V;. '2 · — a compound, 1 tun 4 · ene Propylmethoxy) phenoxy-3 · [(2-methoxyphenoxyethyl) amine 棊 -2 -propanol ([(4-allyl-2-methoxy) phenoxy-3- 2 [( 2- methoxy-phenoxyethyl) amino] -2- propanol) ° 3. —kind of gold, (irK4-nonylamine f-group 4 ▼ oxy) phenoxy-3_ 1 (2-methoxyphenoxyethyl (Amino) amino] -2-salanol l-[(4-nonatriide-2-methoxy) phenoXy] -3-{(2-methoxypheno ^ ethyl) amino] -2_propanol). 4. A compound, (1-K4- is alkenyl_2-methoxy) phenoxy-HQ-methoxyphenylfluorenylcardiyl) pyrrolyl Jr 2 -diol (1 r [(4-propenyl -2-methj〇xy) -phenoxy] -3-[(2-methoxyphetioxyethyl) amino] -_ 2-propanol). 5.-A method for synthesizing the first patent compound in the scope of patent application, which includes: (1) the synthesis of epoxy compound (Epoxide); adding ferulic acid as a wall medium, and boiling after the absolute ethanol After the reaction is completed, an aqueous solution of sodium hydride is added to adjust the pH value to reach neutrality. After concentration under reduced pressure, the product is recrystallized with _A to obtain 4-hydroxy-3-methoxycinnamic acid ethyl ester (4-hydroxy-3 -methoxycinnamic acid ethyl pster) 〇 The product is dissolved in an absolute ethanol solution containing sodium hydroxide, and epichlorohydrine is added for reaction. After the reaction is completed, the solution is concentrated under reduced pressure. The concentrate is filled in Shixi A silica gel column was used for extraction with hexane: acetic acid to separate and obtain crude crystals. Repeatedly recrystallized with hexane to obtain purified 4> (2,3-epoxypropoxy) · 3-methoxycinnamate, (Please read the precautions on the back before filling in this page) Set the paper size printed by the Employees' Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs to apply the Chinese National Standard (CNS) Α4 specification (210X297 mm) 26 Λ% Α8 Β8 C8 D8 Patent application scope ... ........... 1. A compound, (H (4-ethoxycarbonylvinyl · 2 # oxy) phenoxy Each [(2-methoxyphenoxyethyl) amine mashed propanol (ΐ-[(4-ethoxycarbonyLethenyl-2-meth〇5iy) phenoxy] -3-[(2-mdhQ ^ -pJi ^ c ^ ethyL) ainin (^-2-propanol) 〇 • &quot;-V;. '2 · —Compounds, 1 屯 4 · Allylmethoxy) phenoxy_3 · [(2-methoxybenzene [(4-allyl-2-methoxy) phenoxy-3- 2 [(2-allyl-phenoxyethyl) amino] -2-propanol) ° 3.-a kind of gold , (IrK4-nonylamine f-group 4 ▼ oxy) phenoxy-3_ 1 (2-methoxyphenoxyethyl) amino] -2-salanol l-[(4-nona riide- 2-methoxy) phenoXy] -3-((2-methoxypheno ^ ethyl ) amino] -2_propanol). 4. A compound, (1-K4- is alkenyl_2-methoxy) phenoxy-HQ-methoxyphenylfluorenylcardiyl) pyrrolyl Jr 2 -diol (1 r [(4-propenyl -2-methj〇xy) -phenoxy] -3-[(2-methoxyphetioxyethyl) amino] -_ 2-propanol). 5.-A method for synthesizing the first patent compound in the scope of patent application, which includes: (1) the synthesis of epoxy compound (Epoxide); adding ferulic acid as a wall medium, and boiling after the absolute ethanol After the reaction is completed, an aqueous solution of sodium hydride is added to adjust the pH value to reach neutrality. After concentration under reduced pressure, the product is recrystallized with _A to obtain 4-hydroxy-3-methoxycinnamic acid ethyl ester (4-hydroxy-3 -methoxycinnamic acid ethyl pster) 〇 The product is dissolved in an absolute ethanol solution containing sodium hydroxide, and epichlorohydrine is added for reaction. After the reaction is completed, the solution is concentrated under reduced pressure. The concentrate is filled in Shixi A silica gel column was used for extraction with hexane: acetic acid to separate and obtain crude crystals. Repeatedly recrystallized with hexane to obtain purified 4> (2,3-epoxypropoxy) · 3-methoxycinnamate, (Please read the precautions on the back before filling in this page) Set the paper size printed by the Employees' Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs to apply the Chinese National Standard (CNS) A4 specification (210X297 mm) 26 Α8 Β8 C8 D8 S91952 VI. Patent application scope (2) Synthesis of products; take 4- (2,3-Epoxypropoxy) -3-methoxy 丨 Cinnamate Ethyl Acetate 2_ (2-Methoxyphenoxy) ethylamine is dissolved in absolute alcohol and reacts. The mixed liquid iron was concentrated under reduced pressure, and the concentrated solution was separated by a silica gel-filled column. The concentrated solution was sampled into a white crystalline product, and then dissolved in gaseous oxygen (a sodium acetone solution. After the reaction was completed, a tube of Shixi gum was used. After purification, (14 (4-ethoxycarbonylvinyl-2-fluorenyloxy) phenoxy-HOmethoxybenzylethyl) amino] -2-propanol is obtained. / Adrenergic blocking agent active pharmaceutical composition ', which is based on the first compound in the scope of patent application as the main component and added various excipients. 7. A kind of α // 5-adrenergic A pharmaceutical composition that blocks spade activity is based on the second compound in the scope of patent application as the main ingredient. Dare to add | an excipient. (Please read the precautions on the back before filling this page) Ε α 系 会 Α Master _ Medicine for the coating agent to break the item wins 3 Dou Fanfanlili ift i Printed Synthesis Group of the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs, the main subject of the medicine is the agent for the combination of medicines and drugs 4; Solitary The first image of the stimulus m Bu Cang Li ^-Feng shaped kidney application 3-with each β system ^ α added, J1 · Material version Paper size applies to China (CNS) A4 (210X297 mm) 27
TW86114980A 1997-07-31 1997-07-31 Guaiacoxypropanolamines with <alpha>/<beta>-adrenergic blocking activity TW391952B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW86114980A TW391952B (en) 1997-07-31 1997-07-31 Guaiacoxypropanolamines with <alpha>/<beta>-adrenergic blocking activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW86114980A TW391952B (en) 1997-07-31 1997-07-31 Guaiacoxypropanolamines with <alpha>/<beta>-adrenergic blocking activity

Publications (1)

Publication Number Publication Date
TW391952B true TW391952B (en) 2000-06-01

Family

ID=21627089

Family Applications (1)

Application Number Title Priority Date Filing Date
TW86114980A TW391952B (en) 1997-07-31 1997-07-31 Guaiacoxypropanolamines with <alpha>/<beta>-adrenergic blocking activity

Country Status (1)

Country Link
TW (1) TW391952B (en)

Similar Documents

Publication Publication Date Title
FI78479C (en) A FRAMEWORK FOR THERAPEUTIC USE OF THERAPEUTIC MEASURE ARYLOXI-HYDROXIPROPYLENPIPERAZINYLACETANILIDER.
US20120094973A1 (en) Catechol-based derivatives for treating or preventing diabetics
EP0065542A1 (en) Compounds suitable for treatment or prophylaxis of cardiac disorders.
DK157678B (en) METHOD OF ANALOGUE FOR PREPARING AMIDS OF HYDROXYPHENYLALKYLAMINOAETANOLS OR THERAPEUTICALLY ACCEPTABLE SALTS THEREOF AND ACETOPHENE DERIVATIVES USED AS PRESENT MATERIALS
JP2010195828A (en) Stable hydrate of muscarinic receptor antagonist
US20220306638A1 (en) Selective btk irreversible inhibitors
US8558028B2 (en) Compound capable of inhibiting 17-beta hydroxysteriod dehydrogenase
TW391952B (en) Guaiacoxypropanolamines with &lt;alpha&gt;/&lt;beta&gt;-adrenergic blocking activity
NO792113L (en) MEMBRANE-STABILIZING COMPOUNDS THAT HAVE BETA-RECEPTOR BLOCKING ACTIVITY, THEIR PROCEDURES AND PROCEDURES FOR THE TREATMENT OF ARRHYTHMETIC CONDITIONS, AND PHARMASOEYTICAL DISPOSALS AS
CN114853630A (en) 2, 6-diphenylmethylene cyclohexanone oxime compound and preparation method and application thereof
TW467881B (en) Guaiacoxypropanolamines with Α/β-adrenergic blocking activity
DK159435B (en) METHOD OF ANALOGUE FOR PREPARING 2-HYDROXY-5- (1-HYDROXY-2-PIPERAZINYLETHYL) BENZOIC ACID DERIVATIVES OR A PHARMACEUTICAL ACCEPTABLE ACID ADDITION SALT
EP0512525A1 (en) Carbostyril derivatives and pharmaceutical compositions containing the same for use as a disturbance-of-consciousness improving agent, central nervous system stimulant or sigma receptor agonist
JPH0633247B2 (en) 3-Aminopropoxyphenyl derivative, its production method and use
EP0065963A1 (en) Compounds and method for treatment or prophylaxis of cardiac disorders.
NO118172B (en)
US3437731A (en) Method of relieving exaggerated uterine contractions
KR20150088205A (en) Phenoxyacrylic derivatives and use thereof
US10647685B2 (en) Anti-inflammatory 6-phenoxypyrimidine derivatives, process for their preparation and pharmaceutical composition containing them
WO2000005193A1 (en) GUAIACOXYPROPANOLAMINE DERIVATIVES WITH α/β-ADRENERGIC BLOCKING ACTIVITY
TWI228988B (en) A vasorelaxant alpha/beta-adrenoceptor blorker with distinguish antioxidane
DD153682A1 (en) PROCESS FOR PRODUCING NEW ALKANOLAMINE
JPS60156610A (en) Arachidonic acid 5-lipoxygenase inhibitor
KR820001447B1 (en) Process for preparing 3 indolyl tertiary butylaminopropanols
JPS61249957A (en) N-methyl-n-phenylureidethylamine derivative and its production

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MM4A Annulment or lapse of patent due to non-payment of fees